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The ubiquitin-proteasome pathway (UPP) is the principal mechanism for the
selective degradation of short-lived proteins. The proximal signal for UPP-mediated
proteolysis is the covalent modification of target proteins with multiple ubiquitin
polypeptides. Protein-ubiquitin conjugation is catalyzed by ubiquitinating enzymes,
which assemble the polyubiquitin degradation signal on a target protein. It is postulated
that removal of ubiquitin by deubiquitinating enzymes may also regulate protein targeting
to the UPP. However, in comparison to ubiquitinating enzymes, relatively little is known
about the functions or regulation of deubiquitinating enzymes. Dub-1 and Dub-2 are
closely related deubiquitinating enzymes that were initially identified in hematopoietic
cell lines as cytokine-inducible proteins. To gain insights into the substrate(s) and
function(s) of the Dub enzymes, I examined the expression of Dub-1 and Dub-2 mRNA
and protein, and investigated a potential role for these enzymes in regulation of signal
transduction through the nuclear factor-kappa B (NF-kB) family of transcription factors.
Expression analyses indicated that Dub-1 is expressed in the developing murine limb bud
and in interleukin-3-stimulated FL5.12 pro-B cells. To investigate whether the principal
inhibitory protein of NF-kB, IkBa, is a substrate for Dub-1 and Dub-2, a novel in vitro
deubiquitination assay was established using polyubiquitinated IkBa as the substrate. In
addition, I provide evidence for an IkBa-directed deubiquitinating activity in cytoplasmic
lysates from a panel of cell lines. Using this and other complementary assays, I show that
Dub-1 and Dub-2 do not deubiquitinate IkBa, do not stabilize IkBa, and do not modulate
NF-kB activity. In addition, I show that Dub-1, but not the closely homologous Dub-2, is
degraded via the UPP in HEK-293T cells. The UPP-mediated degradation of Dub-1 does
not require an intact Dub-1 catalytic domain, thus indicating that this process does not
proceed via Dub-1-catalyzed transfer of ubiquitin from a substrate to itself. Overall, these
studies provide valuable insights as to the regulation of Dub-1 and Dub-2 that may help
elucidate the substrate(s) and biological role(s) of these enzymes. Furthermore, the
reagents generated for this dissertation will be useful for the study of Dub biochemistry
and IkBa deubiquitination.
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CHAPTER I
GENERAL INTRODUCTION
Protein degradation
The selective degradation of proteins is a crucial process in the maintenance of
cellular function (Kirschner, 1999). In the 1930s, experiments using radiolabelled
compounds to study the kinetics of dietary amino acid uptake and secretion provided
evidence for the dynamic turnover of cellular proteins. These findings raised questions
regarding the earlier assumptions of the stability of cellular constituents (Schoenheimer,
1949). In the 1960s, Schimke and Tomkins demonstrated that protein turnover is highly
selective with their discovery of the short half-lives of regulated enzymes (reviewed in
Schimke and Doyle, 1971). More recently, it has become appreciated that protein
lifetimes range from minutes to days, and several different proteolytic pathways have
been described and shown to be under the control of exquisite regulatory mechanisms
(Kirschner, 1999). Most long-lived proteins are degraded within the lysosome, a
membrane-bound organelle containing a large number of acid-dependent proteases
(Dell'Angelica et al., 2000; Klionsky and Ohsumi, 1999; Mullins and Bonifacino, 2001).
Many short-lived proteins are cleaved by intracellular proteases with specificities for
particular cleavage sites, such as the calpains (Sorimachi and Suzuki, 2001) and the
caspases, which are crucial for apoptosis (Utz and Anderson, 2000). However, the
pathway responsible for the vast majority of selective protein degradation is the
ubiquitin-proteasome pathway (UPP) (Hochstrasser, 1996). The following sections will
2review the biological roles and the machinery of the ubiquitin-proteasome pathway, with
emphasis on the mechanisms that control protein targeting to the UPP.
The Ubiquitin-Proteasome Pathway
An early development in UPP research was the discovery of the ATP-dependent-
degradation of many proteins, including enzymes (Hershko and Tomkins, 1971) or
mutant proteins (Goldberg and St John, 1976). This observation was intriguing,
considering that proteolysis is exergonic and is not expected to require energy.
Description of an ATP-dependent proteolytic system from rabbit reticulocyte lysates
(Etlinger and Goldberg, 1977) provided the framework for the identification of ubiquitin
(Ciechanover et al., 1980; Ciechanover et al., 1978), the 26S proteasome (Hough et al.,
1986), and other components of the UPP.
The UPP is the principal mechanism for the selective degradation of short-lived
proteins (Figure 1.1) (Ciechanover, 1998; Hershko et al., 2000; Pickart, 2000). The list of
proteins processed through the UPP is long and includes cell cycle regulators,
transcriptional activators and inhibitors, cell surface receptors, and damaged or misfolded
proteins (Ciechanover et al., 2000). A wide variety of cellular functions are therefore
influenced by the UPP, including proliferation, differentiation, programmed cell death,
and antigen presentation (Ciechanover et al., 2000). The proximal signal for destruction
through the UPP is covalent modification of target proteins with multiple subunits of
ubiquitin polypeptides. Most polyubiquitinated proteins are degraded by the 26S
proteasome, an ATP-dependent, multicatalytic, multisubunit protease (Voges et al.,
1999).
3
4Several pathways exist to target a protein for destruction by the proteasome.
Many pathways depend on a degradation signal, known as a degron, within a protein that
triggers protein ubiquitination (Varshavsky, 1991). Some degrons are basally active,
while others are controlled by phosphorylation or by interactions with other proteins that
sterically shield the degron from the ubiquitination machinery. Examples of degrons
include the destruction box (D-box) found in cyclins (see below) and the amino-terminal
phosphorylation motif of IkBa (see below). Another type of degron, the N-degron,
consists of a destabilizing amino-terminal residue that targets a protein for ubiquitination
and degradation through a pathway known as the N-end rule pathway (Varshavsky et al.,
2000). In S. cerevisiae, there are two classes of destabilizing amino-terminal residues,
basic or type 1 (arginine, lysine and histidine), and bulky hydrophobic or type 2
(phenylalanine, leucine, tyrosine, tryptophan, and isoleucine). Recent work by
Varshavsky and colleagues has implicated the N-end rule pathway in several processes,
including progression of spermatocytes through meiosis, murine embryogenesis, and
peptide import and chromosome stability in S. cerevisiae (Kwon et al., 2001). Other
pathways target damaged proteins for proteasome-mediated degradation. One such
pathway is the endoplasmic reticulum (ER)-associated degradation (ERAD) pathway,
which targets proteins that are misfolded in the ER for retrograde transport into the
cytosol and degradation through the UPP (Lord et al., 2000).
Ubiquitin-independent degradation of some proteins by the proteasome has also
been described. For example, oxidized proteins are degraded by the 20S core proteasome
in a ubiquitin-independent manner via a process that requires neither ATP nor the 19S
regulatory cap (Davies, 2001). In this process, targeting of oxidized proteins to the
5proteasome appears to occur via oxidation-dependent exposure of hydrophobic domains
and subsequent binding of these domains to the 20S core proteasome. One protein that is
inducibly degraded by the 26S proteasome in a ubiquitin-independent manner is ornithine
decarboxylase (ODC), an enzyme involved in synthesis of polyamines (Coffino, 2001).
In a negative feedback loop, polyamines induce synthesis of antizyme, which binds ODC
and targets it to the 26S proteasome. Recent evidence suggests that p21Cip1 may also be
degraded through a similar pathway (Verma and Deshaies, 2000). It remains to be
determined whether ODC represents an underappreciated class of proteins degraded by
the 26S proteaseome in a ubiquitin-independent manner, or whether ODC is a rare
exception to the general rule of ubiquitin dependence.
Dysregulation of the UPP plays a central role in the pathogenesis of a variety of
human diseases (Schwartz and Ciechanover, 1999), including cancer (Spataro et al.,
1998), neurodegenerative diseases (Lam et al., 2000; Lowe et al., 2001), aging (Friguet et
al., 2000; Gaczynska et al., 2001), and muscle wasting (Mitch and Goldberg, 1996).
Several inherited diseases have also been associated with mutations in components of the
UPP. For example, one inherited form of Parkinson’s disease is caused by mutation of
Parkin, a RING finger E3 ubiquitin ligase (see below), resulting in buildup of an isoform
of a-synuclein (Shimura et al., 2000; Shimura et al., 2001). Many viral pathogens also
subvert the UPP to evade detection by the immune system (Jarrousse et al., 1999) or to
redirect the cellular machinery at various stages of the viral life cycle (Everett, 1999;
Piguet et al., 1999; Vogt, 2000). Since many signal transduction pathways are regulated
by the UPP-mediated destruction of key regulatory proteins, pharmacological
intervention that activates or inhibits the destruction of these regulators is envisioned as a
6promising therepeutic strategy (Rolfe et al., 1997). A thorough understanding of the
mechanisms that target proteins to the UPP is therefore necessary to achieve this goal.
An advantage of the UPP, as compared to other proteolytic pathways, is its
modular nature. Substrate recognition by the UPP is separate from the proteolytic process
itself. Thus, there is no need to evolve different protease specificities for each new
substrate. Components involved in substrate recognition and targeting to the proteasome
include ubiquitin, the ubiquitination machinery (E1s, E2s, and E3s), and the
deubiquitinating enzymes (Figure 1.1). The necessity for tight regulation of this
machinery is underscored by the energy-rich, multistep mechanism of action of the UPP.
However, the precise methods of regulation of the UPP are not fully understood.
Ubiquitin
The proximal signal for protein degradation via the UPP is the post-translational
conjugation of multiple moieties of ubiquitin, a highly conserved 76 amino acid
polypeptide. The role for ubiquitin in proteolysis was discovered through biochemical
fractionation of an ATP-dependent proteolytic activity in rabbit reticulocyte lysates,
which identified one of the necessary components as a small protein that was initially
named APF-1, for ATP-dependent proteolysis factor-1 (Ciechanover et al., 1980). APF-1
was identified as ubiquitin (Wilkinson et al., 1980). Ubiquitin was first identified in the
thymus and was later found in many tissues and organisms, hence its name (Goldstein et
al., 1975). Although ubiquitin is not present in prokaryotes, its sequence is highly
conserved throughout eukaryotes, and 73 out of 76 amino acid residues are identical in
the yeast and the human proteins.
7In addition, there is a growing class of ubiquitin-like proteins (ubls) that share a
high degree of structural similarity to ubiquitin. The ubls frequently have similar
mechanisms of attachment to their target proteins, but exhibit unique biological functions
(Hochstrasser, 2000; Jentsch and Pyrowolakis, 2000; Yeh et al., 2000). Prominent
examples of ubls include SUMO (small ubiquitin-related modifier), which modifies and
regulates the function or subcellular localization of a diverse array of proteins (Muller et
al., 2001), and Rub1 (related to ubiquitin 1), which appears to be critical for the G1/S
transition in S. cerevisiae (Hochstrasser, 1998). Rub1 and its human homologue, NEDD8,
may play crucial roles in the modulation of RING finger/cullin E3 ubiquitin ligase
activity (see below). Ubls, in contrast to ubiquitin, do not appear to assemble into multi-
ubl chains.
Ubiquitin is transcribed as inactive precursor proteins that must be processed by
deubiquitinating enzymes (see below) to form ubiquitin. These precursor proteins exist
either as a fusion of a single amino-terminal copy of ubiquitin and a carboxyl-terminal
ribosomal protein (Finley et al., 1989), or as a fusion of multiple ubiquitin monomers
appended head-to-tail (Ozkaynak et al., 1984). These latter proproteins contain short
carboxyl-terminal peptide extensions that also require removal to form ubiquitin.
Although the purpose of translating ubiquitin as ubiquitin-ribosomal proproteins is not
fully understood, there is evidence that ubiquitin acts as a chaperone for the ribosomal
proteins and aids in proper ribosome biogenesis (see below). However, the primary
function of ubiquitin is to serve as a post-translational protein modification that provides
a signal for protein degradation. Once processed by deubiquitinating enzymes, ubiquitin
can be conjugated to a target protein by the ubiquitin machinery.
8Ubiquitination machinery
Conjugation of ubiquitin to a target protein is ATP-dependent and is achieved by
the sequential actions of members of three enzyme families: the E1, or ubiquitin
activating enzymes; the E2, or ubiquitin conjugating enzymes; and the E3, or ubiquitin
ligating enzymes (Weissman, 2001). These enzymes form an isopeptide bond between
the carboxyl-terminal carboxylate of ubiquitin and the e-amino group of a lysine residue
in the target protein. Multiple rounds of conjugation attach additional ubiquitin molecules
to lysine residues (typically residues 48 or 63) of the first ubiquitin resulting in the
formation of branched polymeric ubiquitin chains or “ladders.” In some cases, an E4
enzyme is also required for efficient elongation of the polyubiquitin chain beyond three
ubiquitin moieties (Koegl et al., 1999).
The first step of ubiquitin conjugation is an ATP-dependent reaction that results in
a high-energy thioester bond between the carboxyl-terminal glycine of ubiquitin and the
active site cysteine of an E1 (ubiquitin-activating) enzyme. In humans, only one E1 gene
has been described (Handley-Gearhart et al., 1994). Studies of a mouse cell line (ts85)
harboring a temperature-sensitive mutant of E1 provided crucial insights into the
functions of the ubiquitin system. First, the absence of ubiquitin-protein conjugation in
these cells at the nonpermissive temperature indicated that activation of ubiquitin by E1
is an obligatory step in protein ubiquitination (Finley et al., 1984). Second, protein
degradation is inhibited in ts85 cells at the nonpermissive temperature, thus indicating
that ubiquitination is required for the degradation of the bulk of abnormal as well as
normally short-lived proteins in vivo (Ciechanover et al., 1984). These observations also
support the view that E1 functions as a basal component of the ubiquitination machinery
9and plays little, if any, role in determining substrate specificity of protein ubiquitination.
Third, the finding that these cells undergo cell cycle arrest (Finley et al., 1984) provided
the groundwork for the subsequent discovery that degradation of cyclins through the UPP
plays a central role in cell cycle progression (Hershko, 1997).
In the second step of ubiquitin conjugation, the activated ubiquitin is transferred
from E1 to the cysteine residue of an E2 (ubiquitin-conjugating) enzyme by
transthiolation. E2-ubiquitin linkages cannot be formed in the absence of an E1. Although
a single E1 appears to be responsible for the first step in all ubiquitination reactions, a
number of different E2s have been identified, including 13 in S. cerevisiae, termed Ubc1-
13, and at least 25 in mammals (Weissman, 2001). All E2s share a core domain
(approximately 15-kDa) that is conserved throughout all family members (Weissman,
2001). Many E2s also have variable amino- and carboxyl-terminal extensions that may
mediate their associations with specific E3s (Mathias et al., 1998). These extensions may
also play a role in substrate selectivity, since degradation of several proteins has been
shown to depend on specific E2s (Haas and Siepmann, 1997). However, in some cases,
different E2s have been shown to support ubiquitination of a single protein, thus
suggesting that a specific role for E2s in determining substrate selectivity is limited. For
example, ubiquitination of the tumor suppressor p53 is mediated by at least three
different human E2s (UbcH5, UbcH6, or UbcH7), which do not appear to represent a
distinct subfamily based on their amino acid sequence (Nuber et al., 1996; Rolfe et al.,
1995; Scheffner et al., 1994).
In the final step of ubiquitin conjugation, ubiquitin is transferred from E2 to the
target protein, resulting in formation of an isopeptide bond between the carboxyl-terminal
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glycine of ubiquitin and the e-amino group of a lysine residue of the target protein. This
reaction is catalyzed by an E3 ubiquitin ligase, which binds the substrate directly and
plays a central role in determining the substrate specificity of ubiquitin conjugation. The
majority of E3s fall into two categories (Weissman, 2001): HECT domain proteins and
RING finger proteins. RING finger E3 ubiquitin ligases can be further subdivided into
single protein RING finger (SPRF) E3 ubiquitin ligases and multisubunit cullin-
containing RING E3s.
HECT domain E3s
The prototype HECT domain protein (homologous to E6-AP carboxyl terminus)
is E6-AP, a cellular protein that is recruited by the human papilloma virus E6 oncoprotein
for the ubiquitination of the p53 tumor suppressor (Scheffner et al., 1993). The HECT
domain is a conserved ~ 350 amino acid domain in the carboxyl terminus of HECT
domain proteins. HECT domain-containing ubiquitin ligases are the only E3s known to
form a thioester bond with ubiquitin (via a conserved cysteine in the HECT domain) prior
to transferring ubiquitin to the substrate protein (Huibregtse et al., 1995). RING finger
E3s (see below), on the other hand, are proposed to catalyze transfer of ubiquitin from E2
to the substrate without proceeding through any such E3-ubiquitin thioester intermediate,
as evidenced by the fact that these enzymes are resistant to alkylating reagents known to
inhibit thioester forming enzymes such as E1 and E2 (Seol et al., 1999). HECT domain
E3s contain divergent amino-terminal domains that function in cognate substrate binding
(Huibregtse et al., 1995). The amino-terminal domain of one HECT E3, KIAA10,
interacts in vitro with purified 26 S proteasomes and with the isolated S2/Rpn1 subunit of
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the proteasome's 19 S regulatory complex (see below), suggesting that the amino-
terminal domains of HECT E3s may function in proteasome binding as well as substrate
binding (You and Pickart, 2001). One family of HECT domain proteins, the
Nedd4/Rsp5p family, mediates ubiquitination and endocytosis of many plasma
membrane receptors, transporters and channels (Jackson et al., 2000; Rotin et al., 2000).
Other HECT domain E3s include Xsmurf1, which regulates the bone morphogenetic
protein (BMP) pathway in Xenopus laevis via ubiquitination of Smad1 (Zhu et al., 1999),
and Pub1, which regulates cell cycle progression in S. pombe via ubiquitination of the
mitotic activating tyrosine phosphatase cdc25 (Nefsky and Beach, 1996).
Single protein RING finger (SPRF) E3 ubiquitin ligases
The RING finger domain (really interesting new gene) is defined as a unique
series of cysteine and histidine residues that binds two zinc ions (Borden, 2000;
Freemont, 2000). Although the RING finger motif was described in the early 1990s
(Freemont, 1993), it was not until 1999 that an association was made between RING
fingers and ubiquitination, when Rbx1 was found to be a necessary component of several
SCF E3 complexes (see below) (Kamura et al., 1999; Ohta et al., 1999; Seol et al., 1999;
Skowyra et al., 1999; Tan et al., 1999). The past few years have seen an explosion in the
understanding of the structure and regulation of RING E3 ubiquitin ligases. The
emerging paradigm is that RING finger E3s can be subdivided into multisubunit RING
finger E3s (see below) and single protein RING finger (SPRF) E3s, which contain the
RING finger and a substrate recognition element. A primary function of the RING finger
domain is to recruit an E2 ubiquitin conjugating enzyme. Subfamilies of SPRF E3s can
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be defined based on domains that exist outside the RING finger domain that may function
to recruit the substrate and other proteins, thus forming large multiprotein complexes
(Borden, 2000). For example, in some SPRF E3s, the RING motif is associated with one
or more B-box domains and a leucine coiled-coil domain. This structure is typified by
Mid1, which targets a recently identified substrate, the catalytic subunit of protein
serine/threonine phosphatase 2A (PP2A) for degradation (Liu et al., 2001). PP2A is
recruited to Mid1 via binding of the PP2A regulatory subunit a4 to the first of two B-
boxes in Mid1 (Trockenbacher et al., 2001). However, other types of SPRF E3s have
diverse structures outside the RING finger domain and are involved in a wide variety of
processes (Borden, 2000). Other prominent examples of SPRF E3s include i) Mdm2,
which ubiquitinates the p53 tumor suppressor (Fang et al., 2000; Honda and Yasuda,
2000); ii) c-Cbl, which binds and ubiquitinates activated receptor protein tyrosine kinases
via an SH2 domain in c-Cbl (Joazeiro et al., 1999; Waterman et al., 1999; Yokouchi et
al., 1999); iii) Parkin, mutations in which are associated with juvenile Parkinson’s disease
(Shimura et al., 2000; Zhang et al., 2000); iv) BRCA1, mutations in which are found in
familial forms of breast and ovarian cancer (Lorick et al., 1999); v) TRAF6, which
mediates cytokin-induced activation of the IkBa kinases (see below); and vi) the
inhibitors of apoptosis (IAP), which are degraded subsequent to autoubiquitination
(Huang et al., 2000; Yang et al., 2000). In addition to the IAPs, several other SPRF E3s
mediate their own stability and/or activity via auto-ubiquitination, including BRCA1 and
Mdm2 (Jackson et al., 2000).
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Multisubunit cullin-containing RING E3 ubiquitin ligases
The third category of E3 ubiquitin ligases are defined by their multicomponent
architecture (Figure 1.2) that includes a RING finger domain-containing protein and a
member of the cullin family of proteins (Jackson et al., 2000; Tyers and Willems, 1999).
These ubiquitin ligases can be classified into at least four families: i) the anaphase-
promoting complex/cyclosome (APC/C) family; ii) the Skp1-Cdc53/Cul1-F-box protein
(SCF) family; iii) the VHL-Elongin C/Elongin B (VCB) family; and iv) the Cul3-based
ubiquitin ligases (Figure 1.2). The structures and functions of SCF complexes and the
APC/C have been elucidated largely through investigations of the cell cycle. SCF
complexes plays a prominent role in regulation of the G1/S transition, while the APC/C
functions in the metaphase-to-anaphase transition and mitotic exit (Tyers and Jorgensen,
2000). APC/C activity is essential for the degradation of several mitotic regulators,
including the anaphase inhibitor Pds1 (which regulates the transition from metaphase to
anaphase) and cyclin B (which regulates the exit from mitosis) (Peters, 1999; Zachariae
and Nasmyth, 1999). A role for the APC/C in meiosis has also recently been described
(Furuta et al., 2000). SCF complexes mediate ubiquitination of a diverse array of
substrates including IkBa, b-catenin, G1 cyclins, Cdk inhibitors, and CD4 (Deshaies,
1999; Willems et al., 1999). Cdc53/Cul1 and Apc2 are members of the cullin family of
proteins that act as scaffolds for the SCF and APC/C, respectively (see Figure 1.2).
Roc1/Rbx1/Hrt1 and Apc11 are RING finger domain-containing proteins, many of which
have been recently implicated in the ubiquitination process (see above) (Lorick et al.,
1999). A third core subunit of SCF complexes is Skp1, which binds the cullin and F-box
14
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subunit (see below) of the SCF and may play a role in optimizing the overall three
dimensional structure of the SCF complex (Deshaies, 1999).
Several mechanisms exist to regulate the activity and substrate selectivity of
RING finger/cullin E3 ubiquitin ligases. The SCF and the APC/C complexes each
contain accessory proteins that may recruit the protein substrate to the ubiquitin ligase
complex. According to the “F-box hypothesis,” each SCF complex contains an accessory
protein, called the F-box protein, that contains an amino terminal ~45 amino acid F-box
domain, which binds directly to Skp1, and a carboxyl-terminal domain, which recruits the
substrate (Bai et al., 1996). The substrate selectivity of the SCF is therefore modulated
via interchange of different F-box proteins. For example, IkBa, b-catenin, and Cubitus
interruptus (Ci) are targeted to SCF via binding to the F-box protein bTrCP (Jiang and
Struhl, 1998; Winston et al., 1999; Yaron et al., 1998). Typically, site-specific
phosphorylation of the substrate is essential for binding of the substrate to the SCF
(Maniatis, 1999). For example, phosphorylation of IkBa on serine residues 32 and/or 36
is essential for binding of IkBa to bTrCP and subsequent recruitment to SCFbTrCP (the
superscript denotes the F-box protein) (Winston et al., 1999).
Accessory proteins for the APC/C complex include the conserved WD40 repeat-
containing proteins Cdc20/Fizzy and Cdh1/Hct1/Fizzy-related, which are presumed to
bind and recruit their substrates to the APC/C in a manner analogous to the F-box
proteins of the SCF (Tyers and Jorgensen, 2000). Thus, binding of Cdc20 and Cdh1 to
the substrate typically depends upon the WD40 repeat region (present in the accessory
protein) and a destruction signal (present in the substrate). The destruction signal in the
substrate consists of either a nine-residue destruction box (D-box) (Glotzer et al., 1991)
16
or a seven-residue KEN box (Pfleger and Kirschner, 2000). APCCdc20 appears to be
specific for D-box-containing substrates (e.g., cyclins A and B). APCCdh1, on the other
hand, recognizes KEN box-containing substrates (including Cdc20 itself), although it also
recognizes some D-box containing substrates as well (Jackson et al., 2000). Cdc20 is also
a component of the mitotic checkpoint complex (MCC), consisting of BubR1, Bub3,
Cdc20, and Mad2, which binds and inhibits the APC/C to prevent premature
chromosome segregation (Hoyt, 2001; Sudakin et al., 2001; Tang et al., 2001). In
addition to these accessory proteins, a large number of additional subunits are present in
the APC/C complex whose functions are only beginning to be understood.
Additional levels of regulation of SCF and APC/C activity occur via post-
translational modification of subunits of the complex. For example, APC/C activity is
regulated by Cdk1- and polo-like kinase-mediated phosphorylation of core subunits
(Zachariae and Nasmyth, 1999). In addition, the ubiquitin ligase activity of SCFbTrCP
towards IkBa is dramatically enhanced by conjugation of the ubiquitin-like protein
NEDD8 to the Cul1 subunit of the SCF (Figure 1.2) (Furukawa et al., 2000; Kawakami et
al., 2001; Read et al., 2000; Tanaka et al., 2001; Wu et al., 2000).
Roles of ubiquitination
The most common role for protein ubiquitination is to target proteins for
degradation by the 26S proteasome. This process generally requires polyubiquitin chains
that are linked through lysine 48 (Lys-48) of ubiquitin and are at least four subunits long
(Thrower et al., 2000). However, ubiquitin modification takes several forms, varying with
respect to the number of ubiquitins per protein and the type of linkage between one
17
ubiquitin moiety and the next (Dubiel and Gordon, 1999). In addition, ubiquitin
conjugation is involved in several proteasome-independent processes. It is becoming
increasingly apparent that different types of ubiquitin modification are associated with
distinct cellular processes.
Protein monoubiquitination is involved in at least three separate functions: histone
regulation, endocytosis and viral budding from the plasma membrane (Hicke, 2001). One
of the earliest protein-ubiquitin conjugates to be discovered was monoubiquitinated
histone H2A (Goldknopf and Busch, 1977; Hunt and Dayhoff, 1977). A role for ubiquitin
modification of histones in the regulation of transcription was suggested by the
observation that much higher levels of ubiquitinated histones H2A and H2B are found in
euchromatic, actively transcribing regions of the genome, than in heterochromatic,
quiescent regions (Davie and Murphy, 1990). Recent experiments have identified the
Rad6 ubiquitin-conjugating enzyme as the E2 that catalyzes ubiquitination of H2A and
H2B (Robzyk et al., 2000). Protein monoubiquitination also plays significant roles in the
regulation of endocytosis of receptors, transporters, and ion channels. Plasma membrane
proteins that are endocytosed via a ubiquitin-dependent process are often targeted for
lysosome-mediated degradation, although in some cases these receptors are degraded by
the proteasome in a process expected to involve Lys-48-linked chains (Rotin et al., 2000).
The E3 ubiquitin ligases involved in ubiquitin-dependent endocytosis of membrane
receptors includes HECT domain E3s and single-protein RING finger E3s such as c-Cbl
(Hicke, 2001). Some observations suggest that viruses may co-opt the host cell
endocytotic machinery to promote budding (Vogt, 2000). For example, a role for
monoubiquitination of retroviral gag proteins has been suggested in the late stages of the
18
budding process (Kikonyogo et al., 2001; Patnaik et al., 2000; Schubert et al., 2000;
Strack et al., 2000; VerPlank et al., 2001).
Of the seven lysine residues in ubiquitin, Lys-11, Lys-29, Lys-48, and Lys-63
have been shown to support polyubiquitin chain formation in vivo (Weissman, 2001). As
mentioned above, 26S proteasome-mediated degradation is generally triggered by Lys-
48-linked polyubiquitin chains. Lys-63-linked polyubiquitin chains, on the other hand,
are important for DNA repair (Spence et al., 1995) and other functions. For example,
TNFa-induced activation of the IkB kinase (IKK) requires polyubiquitination of TRAF6
linked via Lys-63 (see below). Recently, modification of the ribosomal protein L28 by a
Lys-63-linked polyubiquitin chain has been shown to be the most abundant ubiquitinated
protein in S. cerevisiae (Spence et al., 2000). Ablation of L28-ubiquitin conjugate
formation through the use of Lys-63 mutants of ubiquitin renders the cells hypersensitive
to translational inhibitors, thus suggesting a role for L28 ubiquitin modification in the
control of translation (Spence et al., 2000). The functions of Lys-11 and Lys-29
polyubiquitin chains are less well understood (Weissman, 2001).
The proteasome
The 26S proteasome is a 2.5 MDa self-compartmentalized complex responsible
for the degradation of polyubiquitinated proteins. It is composed of a barrel-shaped
proteolytic core, the 20S proteasome, capped on both ends by the 19S regulator (or
PA700), which recognizes polyubiquitinated proteins and is responsible for their ATP-
dependent unfolding and translocation into the 20S core (Ferrell et al., 2000; Voges et al.,
1999) (Figure 1.3). The 20S core is composed of four seven-subunit rings stacked to form
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a narrow-channeled cylinder, a basic structure that is conserved from prokaryotes to
eukaryotes (Kruger et al., 2001). The inner rings are composed of seven b-type subunits,
while the outer two rings are composed of seven a-type subunits. While the prokaryotic
proteasome consists of identical a and b-type subunits, the eukaryotic proteasome is
composed of seven distinct a and b-type subunits. Three of the seven b-type subunits (b1,
b2, and b5) are responsible for the three proteolytic activities: the trypsin-like,
chymotrypsin-like, and peptidylglutamyl-peptide hydrolyzing (PGPH) activities
(Orlowski and Wilk, 2000). These proteolytic activities are confined to the inner chamber
surrounded by the two b-rings and are thereby separated from the environment. Each of
the seven a-type subunits possess an amino-terminal sequence that together form a gate
to hinder entry of proteins through the translocation channel (the opening of the 20S
proteasome). This gate is opened by binding of the 11S or 19S cap, and can also be
opened in vitro by treatment with mild detergents (Kohler et al., 2001).
Several classes of proteasome inhibitors react with the active site threonine of the
b-type subunits (Bogyo et al., 1997; Fenteany and Schreiber, 1998; Lee and Goldberg,
1998). Examples include peptide aldehydes such as MG132, which binds reversibly
(Vinitsky et al., 1992), and the lactacystin derivative clasto-lactacystin beta-lactone,
which binds covalently and irreversibly (Fenteany et al., 1995). The products of both
prokaryotic and eukaryotic proteasome-mediated degradation are peptides 4 to 25
residues long, with an average length of 7 to 9 residues (Ehring et al., 1996; Kisselev et
al., 1998; Nussbaum et al., 1998; Wenzel et al., 1994).
The proteasome plays a major role in immune surveillance through generation of
peptides for presentation on class I major histocompatibility complex (MHC) and
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recognition by the T cell receptor (Kloetzel, 2001). Peptide products of proteasomal
degradation are transported into the endoplasmic reticulum (ER) by the transporter
associated with antigen presentation (TAP) complex and subsequently loaded onto MHC
class I molecules (Elliott, 1997; Momburg and Hammerling, 1998). The efficiency of
generation of some MHC class I epitopes is enhanced by replacement of b-type
proteasome subunits with interferon-g (IFNg)-induced b-type subunits b1i (LMP2), b2i
(MECL1), and b5i (LMP7) to form the “immunoproteasome” (Groettrup et al., 2001).
Immunoproteasomes are enriched over their “constitutive” proteasome counterparts at the
ER, a localization that may facilitate transport of peptides into the lumen of the ER via
the TAP complex (Rivett et al., 2001). It has also been proposed that replacement of the
b-type subunits to form the immunoproteasome results in structural alterations that may
underlie the enhanced generation of epitopes by the immunoproteasome. According to
one proposal, an alteration in the width of the translocation channel leads to a change in
the diffusion rate of digested peptides out of the inner chamber and a subsequent change
in the length of the generated peptides (Kloetzel, 2001). However, the exact mechanisms
of epitope generation by the immunoproteasome remain uncertain, and the precise
immunological role(s) of the immunoproteasome remains unclear (Groettrup et al.,
2001).
The structure of the 19S regulatory complex, also called PA700 (700 kDa
proteasome activator) or the m particle, is less well understood than the 20S core. It is
comprised of two substructures, the base and the lid (Figure 1.3) (Glickman, 2000). The
base contacts the a-ring of the 20S proteasome and may play a role in opening the
translocation channel (i.e. the opening of the 20S particle), which is closed in the free 20S
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proteasome (Kohler et al., 2001). Six of the eight base subunits have ATPase activity
which may play roles in substrate unfolding, gating the translocation channel, and/or
threading the substrate through the channel (Ferrell et al., 2000). One base subunit, S5a
(Rpn10 in yeast), is the only proteasomal subunit found in significant quantities outside
of the 26S proteasome (Haracska and Udvardy, 1995), and is also the only proteasomal
subunit known to bind polyubiquitin chains (Deveraux et al., 1994). Thus, S5a is
suggested to play a role in recruitment of polyubiquitinated substrates to the proteasome.
However, yeast deficient for Rpn10 are viable and can degrade ubiquitin-protein
conjugates (Fu et al., 1998; Rubin et al., 1997; van Nocker et al., 1996), thus suggesting
that one or more additional proteins may be involved in recruitment of ubiquitinated
substrates to the proteasome. The base is sufficient to activate the 20S core for
degradation of peptides or a nonubiquitinated protein; however, the 19S regulator lid is
also required for ubiquitin-dependent degradation (Glickman et al., 1998). The lid
contains eight to ten subunits. However, little is known about their specific functions.
Another regulatory particle besides the 19S cap is the 11S regulatory particle
(which sediments at 11S), also called PA28 (28 kDa proteasome activator) (Li and
Rechsteiner, 2001). This complex consists of seven subunits encoded by two related
genes, REGa and REGb, and confers peptidase activity to the proteasome but does not
promote degradation of intact proteins. Like the b1i (LMP2), b2i (MECL1), and b5i
(LMP7) subunits of the 20S immunoproteasome, REGa and REGb expression is
enhanced by IFNg (Rivett et al., 2001), consistent with the idea that the PA28:20S
proteasome stimulates antigen presentation.
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Deubiquitination
Ubiquitination, like phosphorylation, is reversible. Protein phosphorylation is
controlled by the opposing activities of kinases and phosphatases. In an analogous
manner, the ubiquitination state of a protein is thought to be regulated by both
ubiquitinating and deubiquitinating enzymes (D'Andrea and Pellman, 1998).
Deubiquitinating enzymes are thiol proteases that cleave the peptide bond connecting the
carboxyl-terminal glycine 76 of ubiquitin to an a-amino group (as in the ubiquitin
proproteins) or the e-amino group of the side chain of a lysine residue (Wilkinson, 2000).
Deubiquitinating enzymes that cleave the e-amide bond between ubiquitin and the side
chain of a lysine are also referred to as isopeptidases. The proposed roles of
deubiquitinating enzymes are summarized in Figure 1.4. These enzymes operate at
several levels to generate and maintain the intracellular pool of ubiquitin (Wilkinson,
1997). First, linear ubiquitin proproteins must be processed by deubiquitinating enzymes
to form active ubiquitin. Second, deubiquitinating enzymes salvage ubiquitin that has
been “trapped” by conjugation to small cellular nucleophiles. Third, deubiquitinating
enzymes recycle ubiquitin after protein degradation by the 26S proteasome. In addition,
deubiquitinating enzymes operate at the pre-proteasomal level to “edit” the ubiquitination
state of proteins.
Like protein conjugation to ubiquitin, protein conjugation to ubiquitin-like
proteins (ubl) is also reversible. An exciting recent discovery is the identification of a
novel class of proteases, the ubl-specific proteases (ulp) which deconjugate ubiquitin-like
proteins from their precursor proproteins and/or hydrolyze ubl-protein fusion proteins
(Yeh et al., 2000). Two related yeast ubl-specific proteases, Ulp1 and Ulp2, have been
24
25
identified and shown to deconjugate Smt3 (the yeast homologue of the mammalian ubl
SUMO-1) but not ubiquitin from target proteins (Li and Hochstrasser, 1999; Li and
Hochstrasser, 2000). Computer-assisted homology search revealed at least five human
cDNAs with homology to Ulp1 but not to deubiquitinating enzymes (UBP or UCH; see
below), suggesting there is a family of ubl-specific proteases that are widely distributed
among eukaryotic organisms (Li and Hochstrasser, 1999). However, several
deubiquitinating enzymes have also been reported to function as hydrolases for both
ubiquitin and ubl proteins. For instance, the human UBP enzyme Usp21 has been
reported to hydrolyze both ubiquitin- and ubl-conjugates in vivo (Gong et al., 2000). In
addition, the UCH enzyme UCH-L3 binds to the ubl NEDD8 and cleaves NEDD8
carboxyl-terminal extensions (Wada et al., 1998). The degree of overlap in substrate
specificity between ulps and deubiquitinating enzymes is presently unknown.
Families of deubiquitinating enzymes
Deubiquitinating enzymes are divided by amino acid homology into two families,
the ubiquitin carboxyl-terminal hydrolases (UCH, also known as type 1 UCH) and the
ubiquitin-specific processing proteases (UBP, also known as type 2 UCH) (Chung and
Baek, 1999). UCHs are generally small (less than 30 kDa) containing a 230 amino acid
catalytic core domain. UCHs catalyze ubiquitin proprotein processing and appear to have
a preference for ubiquitin with small carboxyl-terminal extensions. UBPs possess a core
catalytic domain of 350 amino acids and often have large amino- or carboxyl-terminal
extensions or insertions in the catalytic domain, resulting in proteins of 50 to 250 kDa in
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size. In contrast to UCHs, UBPs are thought to be responsible for disassembly of
polyubiquitin chains and removal of ubiquitin from large proteins.
Ubiquitin carboxyl-terminal hydrolases (UCH)
Mutagenesis of UCH enzymes predicted a catalytic core domain consisting of a
triad of cysteine, histidine, and aspartic acid residues (Larsen et al., 1996). Analysis of
the crystal structure of UCH-L3 confirmed this prediction and revealed a catalytic
domain resembling that of cathepsin B, a member of the papain family of thiol proteases
(Johnston et al., 1997). Comparison of this structure to the crystal structure of another
UCH, Yuh1, in a complex with ubiquitin aldehyde provided further insight into the
specificity of deubiquitinating enzymes for ubiquitin (Johnston et al., 1999). These
analyses revealed structures within the UCH that blocked the active site cleft but that
were rearranged upon ubiquitin binding to allow access of the active site to the substrate.
Although the binding sites for ubiquitin have been identified for several deubiquitinating
enzymes and several other proteins (p62 and S5a), no consensus sequence has been
firmly established as a ubiquitin-binding domain (Wilkinson, 2000).
The expression patterns and functions of several UCHs have been analyzed. Two
UCH enzymes, UCH-L1 and -L3, exhibit highly specific patterns of expression, with
UCH-L1 being localized predominantly in the brain and UCH-L3 being expressed
primarily in hematopoetic tissues (Wilkinson et al., 1992). Mutations in UCH-L1 are
associated with diseases of the nervous system, including a small minority of Parkinson’s
disease in humans (Leroy et al., 1998) and gracile axonal dystrophy in the gad mouse
(Saigoh et al., 1999). Another UCH, BAP1, binds to the single-protein RING finger E3
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ubiquitin ligase BRCA1 and enhances BRCA1-mediated growth suppression (Jensen et
al., 1998).
Ubiquitin-specific processing proteases (UBP)
Of the 17 putative deubiquitinating enzymes identified by sequence analysis of
the Saccharomyces cerevisiae genome, 16 belong to the UBP family and only one
belongs to the UCH family (Hochstrasser, 1996). Recent analysis of S. cerevisiae strains
individually deleted for each one of these 17 genes revealed that, surprisingly, all 17
mutant strains were viable (Amerik et al., 2000). Two of the most extensively
characterized UBPs in yeast are Ubp4/Doa4 and Ubp14. Mutation of ubp4/doa4 resulted
in the appearance of small ubiquitinated species and the depletion of intracellular pools of
ubiquitin (Papa and Hochstrasser, 1993). Thus, this enzyme is thought to function late in
the UPP by recycling ubiquitin from remnant peptides after protein degradation by the
proteasome. The yeast Ubp14 and its human homologue, isopeptidase T, hydrolyze
unanchored polyubiquitin chains and presumably work, like Ubp4/Doa4, at the post-
proteasomal level (Hadari et al., 1992). Hydrolysis by isopeptidase T proceeds
sequentially from the proximal end of the ubiquitin chain and is greatly inhibited by the
presence of a protein or other modification at the carboxyl terminus of the proximal
ubiquitin (Wilkinson et al., 1995). Inhibition of isopeptidase T-mediated polyubiquitin
chain disassembly is also associated with some forms of Alzheimer’s disease (Lam et al.,
2000). This process is due to a phenomenon known as “molecular misreading” in which
an error in transcription results in a ubiquitin polypeptide containing an extra 20 amino
acid residues at the carboxyl terminus. These proteins, termed “ubiquitin + 1”, are
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incorporated into isopeptidase T-resistant polyubiquitin chains which accumulate and
inhibit proteolysis by the proteasome.
Several UBPs have been implicated in the control of gene expression in several
organisms. A role for transcriptional silencing in S. cerevisiae has been attributed to two
UBPs, Ubp3 and Ubp10/Dot4, both of which interact with Sir4, a component of the
telomeric silencing complex (Kahana and Gottschling, 1999; Moazed and Johnson,
1996). In Drosophila, the analogous process of position-effect variegation is regulated by
the dosage of another UBP, D-UBP-64E (Henchoz et al., 1996). In the human, the UBP
family member Ubp-M associates closely with mitotic chromosomes and is reversibly
phosphorylated during mitosis, suggesting a role for Ubp-M in the regulation of
chromosome condensation during mitosis, possibly via deubiquitination of histones H2A
and H2B (Cai et al., 1999).
Some deubiquitinating enzymes may promote stabilization of their substrates
Multiple observations support the concept that the functions of deubiquitinating
enzymes may extend beyond purely “housekeeping” purposes to include more
specialized roles. First, the UBP family is the largest family of enzymes within the
ubiquitination system. For example, S. cerevisiae contains 16 UBPs, 3 E1s, 13 E2s, and 7
E3s (Hochstrasser, 1996). This large number of UBPs suggests a heterogeneity of
function that may include the specific regulation of protein polyubiquitination. Second,
many members of the UBP family of deubiquitinating enzymes possess large and highly
divergent amino- or carboxyl-terminal extensions or insertions (Wilkinson, 1997). It is
plausible that these domains may be involved in the regulation of their activities, perhaps
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through modulation of protein-protein interactions and/or subcellular localization. Third,
the highly specific and regulated expression patterns of some deubiquitinating enzymes,
such as the UCH-L1 and L3 proteins (see above), suggest distinct substrate specificities.
Fourth, mutational analyses in higher organisms revealed specific functions for several
deubiquitinating enzymes, as exemplified by the Drosophila UBP fat facets (see below).
In general, few direct analyses have been performed to ascertain the specificities of
deubiquitinating enzymes toward individual polyubiquitinated proteins. Thus, it remains
to be determined whether protein deubiquitination, like protein dephosphorylation, may
modulate signal transduction pathways through the deubiquitination of a specific protein
regulator in the signaling cascade. Several UBPs for which candidate polyubiquitinated
substrates have been identified are discussed below.
Fat facets may deubiquitinate and stabilize its substrate(s)
Mutations in the UBP family member Fat facets (Faf) resulted in elevated
numbers of photoreceptors in each facet of the Drosophila compound eye (Fischer-Vize
et al., 1992). This mutant phenotype was suppressed by mutation of a proteasomal
subunit gene (l(3)73Ai) or a ubiquitin-conjugating enzyme (UbcD1) thus supporting the
idea that Faf deubiquitinates one or more protein substrates and thereby prevents their
degradation by the proteasome (Huang et al., 1995; Wu et al., 1999). Recent evidence
implicated Liquid facets (Lqf) as a critical substrate for Faf. Lqf was identified in a
genetic screen for dominant enhancers of the faf mutant eye phenotype (Fischer et al.,
1997) and found to encode a homologue of epsin, a protein associated with the clathrin-
mediated endocytosis complex (Cadavid et al., 2000). One domain of epsin has recently
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been shown to be structurally similar to a domain of b-catenin (Hyman et al., 2000). The
mouse homologue of Faf, Fam, has been shown to bind and stabilize b-catenin (Taya et
al., 1999). These observations suggest that in the fly, Faf may bind and stabilize Lqf;
however, this conclusion has not been tested biochemically.
In addition to b-catenin, a second potential substrate for Fam is AF-6, a scaffold
protein whose Drosophila homologue, Canoe, is required for eye development
(Miyamoto et al., 1995). Fam binds and deubiquitinates AF-6 in vivo (Taya et al., 1998).
These findings suggest that in the fly, Canoe may be a second substrate for Faf. However,
deubiquitination of AF-6 by Fam has also not been tested biochemically. Furthermore, in
contrast to the case with lqf, canoe mutations do not act as strong dominant enhancers of
the faf mutant phenotype (Cadavid et al., 2000). Thus, the precise substrate specificities
of Fam and Faf remain unclear.
UBPy may deubiquitinate CDC25
Recent evidence indicates that the Ras guanine nucleotide exchange factor
CDC25Mm/Ras-GRF1 may be a substrate for the mouse deubiquitinating enzyme UBPy
(Gnesutta et al., 2001). CDC25Mm contains a large amino-terminal domain that appears to
be essential for CDC25Mm-mediated activation of Ras and Rac1 (Zippel et al., 1996). A
yeast “two-hybrid” system using the CDC25Mm amino-terminal domain as bait identified
UBPy as an interacting partner of CDC25Mm (Gnesutta et al., 2001). This interaction was
verified using glutathione S-transferase “pull down” assays and coimmunoprecipitation
experiments. Further experiments demonstrated that CDC25Mm was polyubiquitinated in
vivo and that UBPy overexpression decreased CDC25Mm ubiquitination and increased
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CDC25Mm half-life (Gnesutta et al., 2001). These results indicate that UBPy may regulate
CDC25Mm–mediated Ras activation via deubiquitination and stabilization of CDC25Mm.
However, an effect of UBPy on Ras activation has not been demonstrated. Furthermore,
deubiquitination of CDC25Mm by UBPy has not been tested in vitro. Therefore, it remains
to be determined whether the observed stabilization of CDC25Mm by UBPy occurs via
direct UBPy-mediated deubiquitination of CDC25Mm.
Proteasome-associated isopeptidases
Several groups have described deubiquitinating activities that are tightly
associated with the 26S proteasome. One group reported a 30-kDa UCH associated with
the 19S regulatory complex that liberates ubiquitin from mono-ubiquitinated lysine
residues of lysozyme (Eytan et al., 1993). This activity differs from other
deubiquitinating activities in that it is unaffected by ubiquitin aldehyde. Another group
has described a ubiquitin-aldehyde sensitive isopeptidase “editing” activity present in the
19S regulatory complex of the proteasome (Lam et al., 1997; Lam et al., 1997), which
disassembles the polyubiquitin chain sequentially from the distal end of the chain and is
proposed to “rescue” poorly ubiquitinated or slowly degraded ubiquitin-protein
conjugates. According to the model proposed by Hershko et al. (Hershko et al., 1980) and
elaborated on by Shaeffer and Cohen (Shaeffer and Cohen, 1996), a low basal level of
nonspecific protein deubiquitination from the distal end of the polyubiquitin chain (away
from the protein) would prevent degradation of proteins modified by short ubiquitin
oligomers, but not by large polyubiquitin chains. However, the proteins that mediate
these two 19S-associated deubiquitinating activities have not been identified.
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A.                                                                              *
Dub-1: 1   MVVALSFPEADPALSSPDAPELHQDEAQVVEELTVNGKHSLSWESPQGPGCGLQNTGNSC 60
Dub-2: 1   MVVSLSFPEQDPALSSPGAQQLHQDEAQVVVELTANDKPSLSWECPQGPGCGLQNTGNSC 60
                                                              GL-N-GNTC
                                                              DH-I
Dub-1: 61  YLNAALQCLTHTPPLADYMLSQEHSQTCCSPEGCKLCAMEALVTQSLLHSHSGDVMKPSH 120
Dub-2: 61  YLNAALQCLTHTPPLADYMLSQEYSQTCCSPEGCKMCAMEAHVTQSLLHSHSGDVMKPSQ 120
           Y-N---QCL
                       *
Dub-1: 121 ILTSAFHKHQQEDAHEFLMFTLETMHESCLQVHRQSKPTSEDSSPIHDIFGGWWRSQIKC 180
Dub-2: 121 ILTSAFHKHQQEDAHEFLMFTLETMHESCLQVHRQSEPTSEDSSPIHDIFGGLWRSQIKC 180
                     QQD--EFL---L--L-E--              S-I---F-G-------C
                     DH-II                            DH-III
Dub-1: 181 LLCQGTSDTYDRFLDIPLDISSAQSVKQALWDTEKSEELCGDNAYYCGKCRQKMPASKTL 240
Dub-2: 181 LHCQGTSDTYDRFLDVPLDISSAQSVNQALWDTEKSEELRGENAYYCGRCRQKMPASKTL 240
           --C-                                          C--C-------K--
                                                         DH-IV
                                                                    *
Dub-1: 241 HVHIAPKVLMVVLNRFSAFTGNKLDRKVSYPEFLDLKPYLSEPTGGPLPYALYAVLVHDG 300
Dub-2: 241 HIHSAPKVLLLVLKRFSAFMGNKLDRKVSYPEFLDLKPYLSQPTGGPLPYALYAVLVHEG 300
           ----LP--L---LKRF--                               Y-L--V--H-G
                                                            DH-V
Dub-1: 301 ATSHSGHYFCCVKAGHGKWYKMDDTKVTRCDVTSVLNENAYVLFYVQQANLKQVSIDMPE 360
Dub-2: 301 ATCHSGHYFSYVKARHGAWYKMDDTKVTSCDVTSVLNENAYVLFYVQQTDLKQVSIDMPE 360
           --------                              -AYVLFY---
                                                 DH-VI
Dub-1: 361 GRINEVLDPEYQLKKSRRKKHKKKSPFTEDLGEPCENRDKRAIKETSLGKGKVLQEVNHK 420
Dub-2: 361 GRVHEVLDPEYQLKKSRRKKHKKKSPCTEDAGEPCKNREKRATKETSLGEGKVXQEKNHK 420
                                                               --Q--NH-
                                                               HV
Dub-1: 421 KAGQKHGNTKL-------------------MPQKQNHQKAGQNLRNTEVELDLPADAIVI 461
Dub-2: 421 KAGQKHENTKLVPQEQNHQKLGQKHRINEILPQEQNHQKAGQSLRNTEGELDLPADAIVI 480
           K-GQ---------Q--NH-K-GQ---------Q--NH-K-GQ-------
                      HV                 HV
Dub-1: 462 HQPRSTANWGRDSPDKENQPLHNADRLLTSQGPVNTWQLCRQEGRRRSKKGQNKNKQGQR 521
Dub-2: 481 HLLRSTENWGRDAPDKENQPWHNADRLLTSQDPVNTGQLCRQEGRRRSKKGKNKNKQGQR 540
                                                        RRSKKGQNKNKQGQR
                                                    p7005
Dub-1: 522 LLLVC 526
Dub-2: 541 LLLVC 545
             LLLVC
B.
Myc:   313 PSTRKDYPAAKRAKLDSGRVLKQISNNR 340
Dub-1: 394 PCENRDKRAIKETSLGKGKVLQEVNHKK 421
Dub-2: 394 PCKNREKRATKETSLGEGKVXQEKNHKK 421
Figure 1.5. Amino acid sequences of Dub-1 and Dub-2. A. Alignment of Dub-1 and Dub-2 proteins.
Residues found to be identical or similar are in white text with black highlights or black text with gray
highlights, respectively. Asterisks denote the positions of the active site cysteine (C), aspartic acid (D), and
histidine (H) residues. Consensus sequences of six deubiquitinating enzyme homology domains (DH-I
through DH-VI) are based on sequence alignment of 15 UBP family members (D’Andrea and Pellman,
1998) and shown under the corresponding Dub-1 and Dub-2 sequences. Also shown are the two or three
hypervariable (HV) regions of unknown function present in the carboxyl terminus of Dub-1 and Dub-2,
respectively. The consensus sequence of HV domains are based on a comparison of these regions. A bar is
drawn above the carboxyl-terminal 20 amino acids to indicate p7005, the peptide used to raise an antibody
to Dub. (See CHAPTER II). LRR: Lysine-rich region. B. Alignment of Dub-1 and Dub-2 with a region of
human c-myc containing the c-myc nuclear localization sequence PAAKRAKLD.
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The dub subfamily of deubiquitinating enzymes
The murine UBP family member, Dub-1, was identified in the pro-B lymphocyte
cell line Ba/F3 by differential display as an immediate-early gene that was induced by
interleukin-3 (IL-3), a cytokine that enhances the growth and survival of early lineage B
lymphocytes (Zhu et al., 1996). Analysis of the predicted amino acid sequence of the
cloned gene indicated that Dub-1 is a member of the ubiquitin-processing protease (UBP)
family of deubiquitinating enzymes (Figure 1.5 – panel A). Coexpression of a glutathione
S-transferase-Dub-1 fusion protein and a ubiquitin-b-galactosidase fusion protein, a
model substrate for deubiquitinating enzymes, in E. coli revealed that Dub-1 has
deubiquitinating activity (Zhu et al., 1996). Mutation of the active site cysteine to serine
(C60S), aspartic acid to asparagine (D133N), or histidine to glutamine (H298Q)
abolished this activity (Baek et al., 2001). Southern analysis of murine genomic DNA
using the Dub-1 open reading frame as a probe revealed the existence of a DUB
subfamily consisting of several homologous members (Zhu et al., 1997). This prediction
was verified by the identification of two additional UBP enzymes, Dub-2 (Zhu et al.,
1997) and Dub-2A (Baek et al., 2001), by homology-based polymerase chain reaction
(PCR) cloning. Both enzymes are highly homologous to the Dub-1 protein. The Dub-2
protein sequence is 88% identical to that of Dub-1, while the Dub-2A protein is 86%
identical to Dub-1. Dub-2 and Dub-2A are even more closely related, sharing 95%
identity. As is the case for Dub-1, Dub-2 and Dub-2A each have deubiquitinating activity
that was abolished by mutation of the active site cysteine to serine (C60S) (Baek et al.,
2001). Sequence analysis of the genomic clones encoding Dub-1, Dub-2, and Dub-2A
revealed a similar genomic organization of two exons separated by a short intron
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corresponding to a region near the amino terminus of the protein (Baek et al., 2001; Zhu
et al., 1997).
Comparison of the sequences of Dub-1 and Dub-2 indicated that they are
members of a discrete subfamily of deubiquitinating enzymes (Figure 1.5 – panel A).
Several features distinguish them from other members of the UBP family of
deubiquitinating enzymes. First, Dub-1 and Dub-2 are highly homologous, not only in the
UBP catalytic domains, but also throughout their entire sequences; in contrast, most UBP
family members have highly divergent regions outside the catalytic domains. Second,
Dub-1 and Dub-2 each possess two to three 19-amino acid “hypervariable” (HV) repeat
regions near the carboxyl terminus (Figure 1.5 – panel A). This HV domain shares some
homology with the c-myc core nuclear localization sequence, PAAKRVKLD (Figure 1.5
– panel B) (Dang and Lee, 1988; Hodel et al., 2001; Makkerh et al., 1996; Post et al.,
2001). However, the function(s) of the Dub-1 and Dub-2 HV region has not been
ascertained.
Several lines of evidence indicate that Dub-1 regulates cellular growth. First,
Dub-1 expression in Ba/F3 cells is dependent upon stimulation by IL-3 (Zhu et al., 1996).
Proliferation of Ba/F3 and other pro-B cell lines is dependent upon stimulation by IL-3,
and cells starved of IL-3 intially arrest in the G1 phase of the cell cycle, followed by
programmed cell death (Palacios and Steinmetz, 1985). Second, inducible overexpression
of Dub-1, but not an inactive Dub-1 mutant C60S, in Ba/F3 pro-B lymphocytes resulted
in G1 arrest without loss of cell viability (Zhu et al., 1996). On the other hand, Dub-1
overexpression did not prevent the induction of apoptosis in cytokine starved Ba/F3 cells
(Zhu et al., 1996), suggesting that the role of Dub-1 in IL-3 signaling may be associated
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with the growth effects of this cytokine. Third, analysis of expression of dub-1 mRNA in
Ba/F3 cells synchronized in early G1 by IL-3 starvation and released by restimulation
with IL-3 revealed that dub-1 expression is highest during the G1 phase of the cell cycle
(Zhu et al., 1996). Although this pattern of cell-cycle-dependent expression was not
tested using other methods of cell synchronization and release, these data suggest that
dub-1 mRNA is expressed in a cell-cycle-dependent manner. Taken together, these
observations indicate that Dub-1 regulates cell growth by regulating the ubiquitination
state of an unidentified growth-regulatory factor, and further indicate that other Dub-1-
related proteins might also be induced by growth factors.
The prediction that other Dub-1 family members may also be induced by growth
factors was confirmed with the observation that Dub-2 is an interleukin-2 (IL-2)-induced
immediate early gene in CTLL-2 murine T lymphocytes (Zhu et al., 1997). IL-2 is a
growth regulatory factor for T lymphocytes that also plays an important role in
maintenance of survival of lymphocytes (Gaffen, 2001). Analyses of the role of Dub-2 in
IL-2-mediated proliferation and survival was investigated recently via overexpression of
wild-type Dub-2 in Ba/F3 cells harboring the IL-2 receptor beta chain IL-2Rb. These
cells (Ba/F3b) survive and proliferate in response to either IL-3 or IL-2 (Migone et al.,
2001). Given the high degree of homology between Dub-1 and Dub-2 (Figure 1.5 – panel
A), it might be expected that overexpression of Dub-2, like Dub-1, would induce cell
cycle arrest but would not prevent apoptosis induced by cytokine withdrawal. Contrary to
this prediction, Dub-2 overexpression prolongs survival following withdrawal of
cytokines from Ba/F3b but has no effect on proliferation (Migone et al., 2001). These
results suggest that Dub-1 and Dub-2 may not be interchangeable, and that they may
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mediate different aspects of cytokine signaling in lymphocytes. For example, Dub-1
might be a mediator of cytokine-regulated cell growth and Dub-2 might mediate
cytokine-regulated cell survival.
The effects of Dub-2 on Ba/F3b cell survival may be explained by the very recent
observation that Ba/F3b cells overexpressing Dub-2 have sustained phosphorylation of
signal transducers and activators of transcription-5 (STAT5) and enhanced expression of
several IL-2-induced genes (Migone et al., 2001). Activation of STAT5 by IL-2 mediates
several aspects of IL-2 signaling, including activation of antiapoptotic proteins such as
Bcl-xL (Gaffen, 2001). Thus it is plausible that Dub-2 mediates cell survival by enhancing
the activation of STAT5 by IL-2. However, it is not known whether regulation of the
JAK-STAT pathway is a general feature of signaling through the Dub-1 family, nor is it
known whether the effects of Dub-2 are limited to regulation of the JAK-STAT pathway.
IL-3 has been shown to regulate the activity of several transcription factors,
including nuclear factor-kappa B (NF-kB) (see below). Withdrawal of IL-3 from the pro-
B lymphocyte cell line, FL5.12, results in a transient decrease in cytoplasmic levels of the
NF-kB inhibitor IkBa, an increase in nuclear levels of the NF-kB subunit c-Rel, and an
increase in NF-kB transcriptional activity (Sohur et al., 2000). Signal transduction
through NF-kB is regulated at many levels by the ubiquitin-proteasome pathway.
Therefore, one potential mechanism by which Dub-1 might mediate cytokine signaling is
through regulation of NF-kB.
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The Nuclear Factor-kappa B family of transcription factors
The NF-kB family of transcription factors was originally discovered as a nuclear
factor that binds to the immunogobulin kappa light chain enhancer (Sen and Baltimore,
1986). Originally thought to be limited in expression to B cells, NF-kB has since been
found to be ubiquitously expressed and to play crucial roles in the regulation of a diverse
array of cellular processes, including proliferation, differentiation, and programmed cell
death (May and Ghosh, 1998). NF-kB plays a central role in the stress and inflammatory
response and is activated by a variety of distinct stimuli including inflammatory
cytokines such as TNFa and IL-1b, T and B cell mitogens, phorbol esters, bacterial
lipopolysaccharide (LPS), oxidative and other stresses, and viral proteins such as the
HTLV-1-transforming protein Tax (Karin and Ben-Neriah, 2000). NF-kB activation is
also involved in the pathogenesis of a wide variety of diseases, including cancer, asthma,
rheumatoid arthritis, inflammatory bowel disease, and AIDS (Baldwin, 2001). Consistent
with these observations, several anti-inflammatory and anticancer drugs, including
nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, and the
immunosuppressants cyclosporin A and FK-506 (Yamamoto and Gaynor, 2001), have
been shown to inhibit NF-kB activation. In addition, NF-kB regulates several aspects of
pre-natal and post-natal development, including the limb bud (Bushdid et al., 1998;
Kanegae et al., 1998), the lung (Muraoka et al., 2000), and the mammary gland (Brantley
et al., 2001; Brantley et al., 2000). Many of these developmental and immunological roles
are conserved between Drosophila and humans (Ghosh et al., 1998).
The molecular mechanisms underlying NF-kB activation have been extensively
studied (Karin and Ben-Neriah, 2000). NF-kB is typically found in the cytoplasm
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associated with a member of the inhibitor-kB (IkB) family of proteins, which holds NF-
kB in the cytoplasm in an inactive state. In response to diverse stimuli, IkB is sequentially
phosphorylated, polyubiquitinated, and degraded by the 26S proteasome, thus allowing
NF-kB to translocate to the nucleus and modulate gene transcription. Many levels of this
pathway are regulated by ubiquitin and the ubiquitin-proteasome pathway (UPP), making
the NF-kB pathway an excellent model system for studying the UPP. The following
sections review the mechanisms of regulation of the NF-kB pathway, placing emphasis
on the components in the pathway that are regulated by ubiquitin.
NF-kB and IkB family members
NF-kB exists as a hetero- or homodimer of members of the NF-kB/Rel family of
proteins (Karin and Ben-Neriah, 2000). There are five family members in mammals:
p100 (p52), p105 (p50), c-Rel, RelA (p65), and RelB (Figure 1.6). Each member of the
NF-kB family contains an amino terminal Rel homology domain (RHD), a ~300 amino
acid domain that mediates dimerization, interaction with IkB, nuclear localization, and
DNA binding. The NF-kB proteins differ in their transcriptional activating capability, and
within the mammalian NF-kB family, only p65 (RelA) and c-Rel have potent
transcriptional activation domains.
Activation of NF-kB is regulated by its cytoplasmic inhibitor, IkB. Mammalian
IkB family members include IkBa, IkBb, IkBg, IkBe, and bcl-3 (Figure 1.6). All IkB
proteins contain six or seven ankyrin repeat regions that bind to the NF-kB RHD and
block the nuclear localization sequence, thus trapping NF-kB in the cytoplasm in an
inactive state. IkBa, IkBb, and IkBe contain amino-terminal regulatory regions that are
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Figure 1.6. Schematic representation of the mammalian and Drosophila NF-kB
and IkB families of proteins. The number of amino acids in each protein is shown on
the right. The Rel Homology Domain (RHD) of NF-kB mediates dimerization, nuclear
localization, and DNA binding. The ankyrin repeat regions of the IkB family are
necessary for binding to NF-kB dimers. Adapted from Karin and Ben-Neriah (2000).
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required for stimulus-induced degradation of IkB and subsequent release of NF-kB. IkBa
is the most well-studied of all IkB family members. Upon receipt of a stimulus, IkBa is
sequentially phosphorylated, polyubiquitinated, and degraded by the 26S proteasome,
thus allowing NF-kB to enter the nucleus and modulate gene transcription (Figure 1.7).
Phosphorylation and ubiquitination of IkBa
Signal-induced degradation of IkBa involves the phosphorylation of IkBa on
conserved serine residue 32 (Ser-32) and Ser-36. Deletion of the amino terminus or
IkBa or mutation of Ser-32 and Ser-36 to alanine residues results in a non-degradable
“super-repressor” IkBa protein that is a potent inhibitor of NF-kB nuclear localization and
transcriptional activation (Brockman et al., 1995; Brown et al., 1995; Chen et al., 1995).
Signal-dependent site-specific IkBa phosphorylation is mediated by the IkB kinases 1 and
2 (IKK1 and 2), which are components of a high molecular-weight (700 to 900 kDa)
multiprotein complex (Chen et al., 1996; DiDonato et al., 1997; Regnier et al., 1997).
Several lines of evidence establish the IKKs as the primary mediators of signal-dependent
IkBa phosphorylation. First, IKK activity is stimulated by the cytokines TNFa and IL-1
with kinetics that match the cytokine-induced phosphorylation of IkBa (Zandi et al.,
1997). Second, IKKs expressed and purified from insect cells phosphorylate IkBa in
vitro, indicating that IKK-mediated IkBa phosphorylation is direct (Zandi et al., 1998).
Third, catalytically inactive versions of IKKs inhibit cytokine-induced NF-kB activation
in a dominant-negative fashion (Mercurio et al., 1997). Therefore, it is not surprising that
the IKKs have been the focus of much attention. Interestingly, IKK activity has recently
been shown to be modulated by ubiquitination (see below).
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Ubiquitination of IkBa by the SCFbTrCP E3 ubiquitin ligase
In response to Ser-32 and Ser-36 phosphorylation, IkBa is rapidly ubiquitinated
on conserved Lys-21 and Lys-22 by a recently described SCFbTrCP E3 ubiquitin ligase
(Maniatis, 1999). Phosphorylated IkBa is recognized by the F-box protein bTrCP, which
binds directly to Ser-32/Ser-36 phosphorylated IkBa but does not bind to the non-
phosphorylated form (Yaron et al., 1998). Several additional targets have been identified
for the mammalian SCFbTrCP complex, including bcatenin (Kitagawa et al., 1999), the HIV
protein Vpu (Bour et al., 2001), the transcription factor ATF4 (Lassot et al., 2001), and
the NF-kB family member p105 (Orian et al., 2000). In most of these cases, bTrCP
recognizes sequences very similar to those encompassing the phosphoacceptor sites of
IkBa, thus indicating that the highly conserved region around the IkBa phosphoacceptor
sites serves as a recognition site for bTrCP.
The current model of IkBa ubiquitination suggests that SCFbTrCP-dependent
ubiquitination of IkBa is regulated principally at the level of IkBa phosphorylation, and
that the ubiquitin ligase activity of SCFbTrCP is constitutive. However, the complex
makeup of SCF ubiquitin ligase complexes offers the possibility that SCF ubiquitin ligase
activity may itself be regulated. For example, it has recently been reported that
recognition of IkBa by SCFbTrCP is enhanced by conjugation of the ubiquitin-like protein,
NEDD8, to Cul1 (Figure 1.2) (Wu et al., 2000). Furthermore, the stability of NEDD8 has
recently been shown to be regulated by a novel, interferon-induced NEDD8-interacting
protein, NUB1 (NEDD8 ultimate buster-1), which recruits NEDD8 to the proteasome for
degradation (Kamitani et al., 2001; Kito et al., 2001). These results indicate that the
regulation of the SCF ubiquitin ligase machinery may be more complex than previously
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appreciated. Other means also exist to regulate the polyubiquitination of IkBa that are
independent of IkBa Ser-32/Ser-36 phosphorylation. For instance, conjugation of the
ubiquitin-like protein SUMO-1 to Lys-21 of IkBa has been reported to render IkBa 
resistant to signal-induced polyubiquitination and degradation of IkBa, thereby
antagonizing NF-kB activation (Desterro et al., 1998).
Limited proteolysis of p100 and p105 by the UPP
In most cases, proteins that are targeted to the 26S proteasome via
polyubiquitination are degraded completely. The limited processing of p100 and p105 to
the NF-kB subunits p52 and p50, respectively, by the UPP is a notable exception
(Silverman and Maniatis, 2001). These subunits are derived from the amino-terminal
domains of p100 and p105 via degradation of the carboxyl-terminal ankyrin repeat
domains (Figure 1.6). Two potential mechanisms have been proposed to account for the
generation of p52 and p50. By one mechanism, p105 and p100 are generated as full-
length precursor proteins that undergo limited proteolysis to form p50 and p52
(Silverman and Maniatis, 2001). However, another mechanism has been proposed in
which proteasome-mediated processing begins before translation of full-length p100 or
p105 is complete, a process termed cotranslational processing (Heusch et al., 1999; Lin et
al., 1998). After processing, the active p50 and p52 subunits heterodimerize with other
members of the NF-kB family, such as p65, to generate active NF-kB. Processing of p100
and p105 is stimulated by NF-kB-activating signals (Heissmeyer et al., 1999; Orian et al.,
2000). In addition, signal-dependent phosphorylation and ubiquitination of these proteins
may be mediated by IKK (Heissmeyer et al., 1999) and SCFbTrCP (Orian et al., 2000),
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respectively. However, the extent to which stimulated processing of these subunits
contributes to NF-kB activation is unclear (Silverman and Maniatis, 2001).
Regulation of IKK by ubiquitin
Studies of the regulation of IKK activity have uncovered a novel regulatory
function for ubiquitin that does not involve the proteasome. Early biochemical analysis of
IKK revealed that kinase activity was dependent on the presence of an E1, an E2, and
ubiquitin but did not depend on proteolysis (Chen et al., 1996), thus suggesting that an
unusual ubiquitination event is required for IKK activation. Recently, the cytokine-
induced activation of IKK through the TNF receptor-associated factor 6 (TRAF6) was
shown to require a heteromeric complex containing the ubiquitin conjugating enzyme
Ubc13 and the E2-like protein Uev1A (Deng et al., 2000). This complex was found to
facilitate cytokine-induced auto-polyubiquitination of TRAF6, an E3 ubiquitin ligase (see
above) (Wang et al., 2001). In addition, TRAF6-conjugated polyubiquitin chains were
linked via Lys-63, and formation of these chains was necessary for IKK activation.
However, cytokine-mediated activation of IKK through TRAF6 did not require
proteasome-mediated proteolysis. This discovery supports the paradigm of a non-
proteolytic role for Lys-63-linked polyubiquitin chains and underscores the complex roles
played by ubiquitin in the regulation of signal transduction.
Summary
The last few years have witnessed tremendous advances in our understanding of
the mechanisms by which proteins are recognized and degraded by the UPP. In addition,
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many non-proteolytic roles have been discovered for ubiquitin and for ubiquitin-like
proteins. The plethora of biological events regulated by ubiquitin suggest that protein
ubiquitination is tightly regulated. The recent indications that some deubiquitinating
enzymes may rescue their substrates from UPP-mediated degradation suggest that protein
deubiquitination may play a central role in the control of protein degradation. However,
compared with other aspects of the ubiquitin-proteasome pathway, relatively little is
known about the functions of deubiquitinating enzymes. To begin to address these issues,
I focused my research efforts on two UBP family members, Dub-1 and Dub-2. In Chapter
II, I present the characterization of a Dub-1 carboxyl terminus antibody and analyses of
the expression of Dub-1 and Dub-2. These data indicated that Dub-1, but not Dub-2, is
itself a target for proteolysis by the UPP. Further analyses indicated that dub-1 mRNA is
expressed in the developing murine limb, and that mRNA and protein are expressed in
IL-3-stimulated FL5.12 pro-B cells. I hypothesized that the NF-kB pathway may be
regulated by Dub-1 and Dub-2. In particular, I hypothesized that IkBa may be the target
for the deubiquitinating activity of Dub-1 and Dub-2. In Chapter III, I present a novel in
vitro assay for monitoring the deubiquitination of IkBa and present the first direct
evidence that IkBa is a target for deubiquitinating activity. In Chapter IV, I use this and
other assays to test the hypothesis that Dub-1 and Dub-2 regulate the NF-kB pathway.
These data indicate that Dub-1 and Dub-2 do not deubiquitinate IkBa, and further
experiments indicate that Dub-1 and Dub-2 do not regulate IkBa stability or NF-kB
activation. In Chapter V, I summarize the impact of these results on the potential
functions of Dub-1 and Dub-2, as well as a potential role for IkBa deubiquitination in the
control of NF-kB signaling.
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CHAPTER II
ANALYSIS OF DUB EXPRESSION
Introduction
Dub-1 was originally identified in the murine pro-B cell line Ba/F3 as an
interleukin-3 (IL-3)-inducible immediate early gene whose overexpression arrests cells in
the G1 phase (Zhu et al., 1996). Work from the Kerr lab using a second murine pro-B cell
line, FL5.12, demonstrated that IL-3 regulates signal transduction through the NF-kB
pathway (Sohur et al., 2000). It has been shown that NF-kB regulates the G1/S transition
in several cell types (Joyce et al., 2001). Furthermore, the NF-kB inhibitor, IkBa, is
degraded through the ubiquitin-proteasome pathway (UPP). Therefore, I hypothesized
that Dub-1 acts on the cell cycle through the NF-kB pathway by deubiquitinating IkBa
and preventing activation of NF-kB.
In this chapter, I examine the relationship between Dub-1 and the NF-kB
signaling pathway through mRNA and protein localization studies. In the avian embryo,
the NF-kB family member c-rel is highly expressed in the developing limb buds and
plays a role in limb development (Abbadie et al., 1993; Bushdid et al., 1998; Bushdid et
al., 2001; Kanegae et al., 1998). To determine whether dub-1 expression correlates with
expression of c-rel during murine embryogenesis, the expression of dub-1 and c-rel
mRNA was examined in the developing limb bud of the mouse by whole mount in situ
hybridization. It has already been shown that withdrawal of IL-3 from FL5.12 cells
results in degradation of IkBa, translocation of the NF-kB subunit c-Rel to the nucleus,
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and an increase in NF-kB transcriptional activity (Sohur et al., 2000). Therefore, I
determined the fate of dub-1 mRNA and protein in IL-3 starved FL5.12 cells. To examine
the expression of protein in these cells, a rabbit antibody was raised against a peptide
derived from the carboxyl terminus of Dub-1. This antibody was extensively
characterized and utilized to monitor cytokine-regulated changes in Dub expression and
UPP-mediated ubiquitination and degradation of Dub proteins.
Materials and Methods
Cell lines and culture
FL5.12 (murine pro-B lymphocyte) cells were cultured at 370C/5% CO2 in RPMI
1640 (Mediatech, Inc., Herndon, VA) supplemented with 10% heat-inactivated fetal calf
serum, 2 mM L-glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin, 50 mM b-
mercaptoethanol,  and 10% Wehi-3B-conditioned medium as a source of interleukin-3
(Sohur et al., 2000). For IL-3 starvation, FL5.12 cells were washed three times in ice-cold
phosphate-buffered saline (PBS) and resuspended in culture medium lacking Wehi-3B-
conditioned medium. HEK-293T cells (human embryonic kidney epithelial cells
expressing the SV40 large T antigen) were cultured at 370C/5% CO2 in Dulbecco’s
modified Eagle medium (Mediatech, Inc.) supplemented with 10% heat inactivated fetal
calf serum, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 mg/ml streptomycin.
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Generation of Dub antiserum
Rabbit antiserum was raised against a synthetic peptide corresponding to the
carboxyl terminus of Dub-1 (RRSKKGQNKNKQGQRLLLVC from Chiron Mimotopes
Peptide Systems, San Diego, California). This peptide is identical to the carboxyl
terminus of Dub-2 in all but one amino acid residue (see Figure 1.5). Immunizations and
bleeds were performed in collaboration with the Molecular Recognition Unit (Vanderbilt
University Medical Center). The peptide was conjugated to maleimide-activated BSA
(Pierce, Rockford, Illinois) and injected into a New Zealand White rabbit. Prior to antigen
injection, the rabbit was bled via an ear vein to obtain preimmune serum. One hundred
micrograms of peptide/BSA conjugate in PBS was emulsified in one ml of RIBA (RIBA
Immunochem research, Inc., Hamilton, MT). Rabbits were immunized via subcutaneous
(SC) and intradermal (ID) routes on day 0 using 0.05 ml (ID) and 0.1 ml (SC) of antigen
per site (1 ml total per immunization). Four weeks post immunization, rabbits were bled
via an ear vein, then immunized again as above. Rabbits were bled and immunized every
two weeks thereafter to obtain antiserum. The antiserum was partially purified by
precipitation with caprylic acid followed by ammonium sulfate precipitation. For
Western analysis, partially purified antiserum was diluted in 0.2% Tween/TBS containing
0.5% BSA.
Western analysis
Protein samples were fractionated by SDS-PAGE (10% polyacrylamide gels ) and
transferred to Immobilon P membranes (Millipore, Bedford, MA) by electroblotting.
Specific proteins were detected by probing membranes with diluted primary antibody,
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followed by alkaline phosphatase-conjugated or horseradish peroxidase-conjugated
secondary antibody and colorimetric detection (BCIP/NBT) or chemiluminescence
(Renaissance Western Blot Chemiluminescence Plus, NEN Life Science, Boston, MA),
respectively. Peptide competition assays were performed as described in the legend to
Figure 2.3.
Whole-mount in situ hybridization
Murine embryos were analyzed by whole-mount in situ hybridization in
collaboration with Paul Bushdid as described (Hogan, 1994). Sense and antisense c-rel
riboprobes were synthesized as reported previously (Bushdid et al., 1998). To produce a
dub-1 antisense RNA probe, the dub-1 cDNA was subcloned into pcDNA3 (Zhu et al.,
1996), linearized using HpaII, transcribed with Sp6 RNA polymerase, and digoxigenin-
labelled according to manufacturer’s specifications (Boehringer). The resulting probe
corresponded to the 505 nucleotides at the 3’ end of the dub-1 open reading frame (ORF).
Embryos from C57BL/6 mice were fixed overnight at 40C in 4% paraformaldehyde
(PFA), washed briefly with PBS, and stored in 100% methanol at –200C until processed.
The day of hybridization, embryos were rehydrated in PBS + 0.1% Tween 20 (PBST).
The embryos were permeabilized with 10 mg/ml proteinase K and refixed with 4% PFA
for 20 minutes at room temperature. After washing in PBST, the embryos were
prehybridized in hybridization buffer (50% deionized formamide, 4x SSC, pH 7.0, 50
mg/ml tRNA, 0.5 mg/ml heparin, and 1% SDS) for 2 hours and then hybridized overnight
at 700C in buffer containing digoxigenin-labeled cRNA (1 mg/ml). The embryos were
washed in Solution I (50% deionized formamide, 5x SSC, pH 7.0, and 1% SDS) two
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times for 30 minutes at 700C, one time for 30 min at 650C, and three times in Solution II
(50% deionized formamide, 2x SSC, and 0.5% SDS) for 30 minutes at 650C. The
embryos were then washed three times in TBS + 1% Tween 20 (TBST) before blocking
in TBST + 10% heat-inactivated sheep serum for 2.5 hours at room temperature. The
block solution was removed and anti-DIG F(ab)2 fragments conjugated to alkaline
phosphatase (diluted 1:2000 dilution in TBST + 1% serum) was added and the embryos
were incubated at 40C overnight. Following extensive washing in TBST containing 1 mM
levamisole, labeled cRNA was visualized using the NBT/BCIP colorimetric reaction.
Embryos were graded into 80% glycerol for photography.
Ribonuclease protection assays
Dub-1, L32 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA
levels in FL5.12 total RNA preparations were analyzed using the RiboQuant Multi-Probe
RNase Protection Assay System according to the manufacturer’s instructions
(PharMingen, San Diego, CA). 32P-Labeled antisense RNA templates specific for L32
and GAPDH were transcribed from the mCK-1 Custom Template Set (PharMingen). To
produce a dub-1 32P-labelled antisense RNA probe, pcDNA3-Dub-1 was linearized using
HpaII and transcribed in the presence of 32P-dCTP with Sp6 RNA polymerase. Total
RNA was isolated from FL5.12 cells using Tri-Reagent (Molecular Research Center,
Cincinnati, OH) according to the manufacturer’s instructions. Twenty micrograms of
total RNA was analyzed per reaction.
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Immunoprecipitations
HEK-293T cells were transiently cotransfected with a mammalian expression
vector encoding HA-ubiquitin and with an empty vector or a mammalian expression
vector encoding Dub-1 (wild type or C60S) or Dub-2 (wild type or C60S) (5 mg of each
plasmid per 10-cm dish) by calcium phosphate precipitation and glycerol shock
(Sambrook et al., 1989). Thirty-six hours post-transfection, cells were incubated with
MG-132 (40 mM) or DMSO for 8 hours, followed by washing in ice-cold PBS and lysis
in ice-cold Lysis Buffer A (see CHAPTER III). Cell lysates were centrifuged at 15,000 x
g for 10 minutes at 40C and the pellet was discarded. Protein concentration of the
clarified lysates was determined using the DC Protein Assay kit (Bio-Rad Laboratories,
Hercules, CA). Lysates were diluted to 2 mg/ml in Lysis Buffer A, and
immunoprecipitations were performed from 1 ml of diluted lysates using 30 ml of a 50%
slurry of Anti-HA Affinity Matrix (Roche, Indianapolis, IN). The immune complexes
were washed five times in Lysis Buffer A, solubilized in SDS-sample buffer, and
analyzed by immunoblotting.
Results
Dub expression during embryogenesis
To examine the expression of dub-1 and c-rel mRNA during embryogenesis,
whole-mount in situ hybridizations were performed on murine embryos harvested at 11.5
days post-coitus (d.p.c) using dub-1 and c-rel antisense RNA probes (Figure 2.1). A c-rel
sense probe was used as a negative control for hybridization. Additional controls for
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dub-1 Antisense
Figure 2.1. Expression of dub-1 and c-rel in the developing mouse. Whole-mount in
situ hybridizations for dub-1 and c-rel mRNA were performed on murine embryos
harvested at 11.5 days post coitus (d.p.c.) using digoxigenin-labelled antisense RNA
probes for murine dub-1 or c-rel, or a sense RNA probe for c-rel. A representative of at
least three embryos is depicted for each probe.
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nonspecific trapping of the probe in the body of the embryo included hybridizations
performed concurrently with sonic hedgehog (shh) and fibroblast growth factor-4 (fgf-4)
antisense RNA probes, each of which revealed a unique pattern of expression in the limb
(Strayhorn and Bushdid, data not shown). These experiments demonstrated that dub-1
mRNA, or a homologous mRNA that hybridizes with the dub-1 antisense probe, is
expressed in the developing limb bud and pharyngeal arches in a pattern that partially
overlaps that of c-rel. NF-kB activity is necessary for proper limb bud development in the
chick (Bushdid et al., 1998; Kanegae et al., 1998) and may mediate FGF-induced
expression of msx-1 during normal limb development (Bushdid et al., 2001). The
observation that the pattern of expression of dub-1 is closely aligned with that of c-rel is
consistent with the proposed role for Dub-1 in the regulation of the NF-kB signal
transduction pathway (see INTRODUCTION to this chapter).
Characterization of Dub-1 carboxyl terminus antibody
To examine the expression of Dub-1 in target cells, rabbit antibodies were raised
against a peptide derived from the carboxyl terminus of Dub-1 (see MATERIALS AND
METHODS). This peptide is identical to the 20 amino acids at the carboxyl terminus of
Dub-1 and matches 19 of the 20 amino acids at the carboxyl terminus of Dub-2 (see
Figure 1.5). Lysates of HEK-293T cells transfected with empty vector (Figure 2.2, lane
2) or with a plasmid encoding Dub-1 (wild type, lane 3; C60S, lane 5) or Dub-2 (wild
type, lane 4; C60S, lane 6) were analyzed by immunoblotting with the rabbit antiserum.
The predominant protein detected in each Dub-overexpressing sample (lanes 3 - 6)
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Figure 2.2. Characterization of a Dub-1 carboxyl terminus antibody. HEK-293T
cells were transiently transfected with empty vector (lane 2) or with mammalian
expression plasmids encoding Dub-1 (wild type, lane3; C60S, lane 5) or Dub-2 (wild
type, lane 4; C60S, lane 6). Cell lysates were prepared 48 hours post-transfection and an
aliquot (5 mg) was analyzed by immunoblotting with the Dub-1 carboxyl terminus
antibody (top panel). Endogenous Dub-1 was visualized in FL5.12 cell lysates (5 mg)
(lane 1). As a loading control, the membrane was stripped and reprobed with an
antibody recognizing the catalytic subunit of PP2A (PP2AC; bottom panel). The
migration of prestained SDS-PAGE standards is shown on the left.
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migrated at rates consistent with the predicted migration rates of Dub-1 and Dub-2, which
are 526 and 545 amino acids in length, respectively (Figure 1.5) (Zhu et al., 1996; Zhu et
al., 1997). These results indicate that exogenous Dub-1 and Dub-2 proteins are indeed
recognized by the Dub antisera.
FL5.12 cells were predicted to express endogenous Dub-1 since Dub-1 expression
is induced by IL-3 in another pro-B cell line, Ba/F3 (Zhu et al., 1996), and FL5.12 cells
require IL-3 for growth and viability (Boise et al., 1993; McKearn et al., 1985).
Furthermore, reverse-transcription polymerase chain reaction (RT-PCR) of FL5.12 RNA
using primers that recognize dub-1 and dub-2 (as determined using dub-1 and dub-2
cDNAs as the templates for the PCR reactions) produced a DNA product of the expected
size for dub-1 (~ 1.6 kb) but not dub-2 (~ 1.7 kb; data not shown). To determine whether
the Dub-1 carboxyl terminus antiserum recognizes endogenous Dub-1, immunoanalysis
was performed on lysates of FL5.12 cells (Figure 2.2, lane 1). A single protein was
visualized in this sample that comigrated with exogenous Dub-1 expressed in HEK-293T
cells (compare lane 1 to lanes 3 and 5). To verify that recognition of the protein in
FL5.12 extracts was mediated by a specific antibody-protein interaction, peptide
competition assays were performed (Figure 2.3) with peptide p7005 (used in the
generation of Dub-1 antiserum) and peptide p7002 (corresponding to a 20 amino acid
sequence within the Dub-2 hypervariable region). FL5.12 cell lysates were fractionated
by SDS-PAGE and transferred to a nylon membrane. Strips of the membrane were
blocked in TBST/5% milk and then incubated with varying combinations of primary
antibody, antibody diluents, and blocking peptide as indicated in the legend to Figure 2.3.
Strips were then probed with AP-conjugated (left panel) or HRP-conjugated (right panel)
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Figure 2.3. Competition of Dub-1 antibody binding by synthetic peptides. FL5.12
cell lysates were fractionated by SDS-PAGE and transferred to a nylon membrane,
which was then cut into thin, identical strips. Strips (containing approximately 10 mg per
strip) were blocked in TBST/5% milk prior to incubation with the indicated rabbit
primary antibody: i) antibody raised against full length (FL) GST-Dub-1 (a gift from Dr.
Alan D’Andrea); ii) antibody raised against peptide p7005 corresponding to the
carboxyl terminus (C-term) of Dub-1 (W.D.S.); or iii) no antibody. The primary
antibody was diluted 1:4000 (C-term) or 1:500 (FL) in TBST containing either 5% milk
or 0.5 mg/ml BSA as indicated. The blocking peptides p7002 (an unrelated peptide) or
p7005 were added to the diluted antibodies as indicated at a concentration of 1 mg/ml.
After incubation with the 10 antibody, strips were incubated with goat anti-rabbit AP-
conjugate (left panel) or goat anti-rabbit HRP-conjugate (right panel) secondary
antibodies, and bound antibodies were visualized by colorimetric detection or
chemiluminescence, respectively. The migration of prestained SDS-PAGE standards is
shown on the left.
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secondary antibodies and visualized by colorimetric detection or chemiluminescence,
respectively. No proteins were visualized in strips that were probed with secondary
antibodies alone (lanes 1 and 8). A single protein was visualized on strips that were
probed with the Dub-1 carboxyl terminus antiserum diluted in TBST and 0.5% BSA
(Figure 2.3, lanes 4 and 11; indicated with the filled arrow). This protein comigrated with
the predominant protein visualized using the full-length (FL) GST-Dub-1 antibody
(compare lanes 2 and 3 to lane 4 and lanes 9 and 10 to lane 11). The immunodetection of
this protein by the Dub-1 carboxyl terminus antiserum was abrogated when peptide
p7005 (corresponding to the carboxyl terminus of Dub-1) was included in the primary
antibody diluent (compare lane 4 to 5 and lane 11 to 12). However, visualization of this
protein by the Dub-1 carboxyl terminus antibody was not affected when an unrelated
peptide (p7002) was included in the primary antibody diluent. Similar experiments
demonstrated that immunodetection of exogenous Dub-1 and Dub-2 using this antibody
was likewise abrogated by specific peptide but not by an unrelated peptide (data not
shown). These data indicate that the recognition of Dub-1 and Dub-2 by the Dub-1
carboxyl terminus antiserum is mediated by specific antibody-protein interaction and that
endogenous Dub-1 protein is expressed in FL5.12 cells.
Since peptide p7005 was conjugated to BSA prior to immunization (see
MATERIALS AND METHODS), I examined whether the Dub-1 carboxyl terminus
antiserum might recognize albumin present in lysates of FL5.12 cells, either due to
endogenous albumin in FL5.12 cells or due to residual BSA from the cell culture media.
Therefore, strips containing FL5.12 cell lysates were probed with Dub-1 carboxyl
terminus antiserum that was diluted in TBST/0.5% BSA (lanes 4 and 11) or in TBST/5%
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milk (lanes 7 and 14), and the results of the two diluents were compared. Dilution of the
antiserum in milk resulted in visualization of a protein migrating slightly more slowly
than Dub-1, consistent with the identification of this band as albumin, which is 607
amino acids long in the cow and 608 amino acids long in the mouse (Carninci and
Hayashizaki, 1999; Hilger et al., 2001) (Dub-1 is 526 amino acids long; see Figure 1.5).
However, this protein was not detected when the antiserum was diluted in BSA (compare
lane 7 to lane 4 and lane 14 to lane 11), which would serve to adsorb albumin-specific
antibodies in the antiserum. Therefore, to prevent the immunodetection of albumin by the
Dub-1 carboxyl terminus antibody, TBST/0.5% BSA was used as the diluent in all
subsequent immunoanalyses using this antibody.
Regulation of Dub-1 by interleukin-3 in FL5.12 cells
To verify the expression of Dub-1 in FL5.12 cells, a ribonucease protection assay
(RPA) was performed on total RNA from FL5.12 cells using a riboprobe derived from
the 505 nucleotides at the 3’ end of the dub-1 open reading frame (see MATERIALS
AND METHODS). Analysis of total RNA prepared from FL5.12 cells using this
riboprobe resulted in visualization of a protected fragment that migrated at the predicted
rate on a polyacrylamide gel (Figure 2.4 – A, top panel, lane 1), thus indicating the
presence of dub-1 mRNA in FL5.12 cells.
Since Dub-1 expression is regulated by IL-3 in the pro-B lymphocyte cell line
Ba/F3 (Zhu et al., 1996), I tested whether Dub-1 expression is regulated in a similar
manner by IL-3 in FL5.12 cells. Total RNA was prepared from FL5.12 cells that were
starved of IL-3 for varying amounts of time, and ribonuclease protections were
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Figure 2.4. Regulation of Dub-1 expression in FL5.12 cells. A. FL5.12 cells were
starved of interleukin-3 (IL-3) for the indicated times, and total RNA was prepared.
Ribonuclease protection assay (RPA) was performed on RNA samples (20 mg) using
probes specific to Dub-1 (top panel), or to L32 and GAPDH (bottom panel). B. FL5.12
cells were cultured in the presence of IL-3 (lanes 1 and 4), starved of IL-3 for 12 hours
(lanes 2 and 5), or starved for 12 hours and then restimulated (Restim.) with IL-3 for 3.5
hours. Western analysis was performed on cell lysates (20 mg) using an antibody raised
against full length GST-Dub-1 (top left panel) or the Dub-1 carboxyl terminus (top right
panel). As a loading control, membranes were stripped and reprobed with an antibody
to the catalytic subunit of PP2A (PP2AC) (bottom panels). The migration of prestained
SDS-PAGE standards is shown on the left. Each experiment was performed a minimum
of two independent times.
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performed to monitor levels of dub-1 mRNA (Figure 2.4 – A, top panel). L32 and
GAPDH were used as internal loading controls for this assay (Figure 2.4 – A, bottom
panel). These experiments revealed that dub-1 mRNA decreases following IL-3
deprivation of FL5.12 cells. To determine whether expression of Dub-1 protein is also
regulated by IL-3, immunoanalyses using the antibody raised against full length GST-
Dub-1 (Figure 2.4 – B, top left panel) or using the Dub-1 carboxyl terminus antibody
(Figure 2.4 – B, top right panel) was performed on lysates from rapidly proliferating
FL5.12 cells (lanes 1 and 4), FL5.12 cells that had been starved of IL-3 for 12 hours
(lanes 2 and 5), and FL5.12 cells that had been starved and then restimulated with IL-3
for 3.5 hours (lanes 3 and 6). To verify equivalent loading, the membranes were stripped
and reprobed with an antibody to the catalytic subunit of PP2A (PP2A/C, bottom panels).
These results indicated that Dub-1 protein expression is regulated by IL-3 in FL5.12
cells. Since IL-3 also regulates the stability of IkBa in these cells (Sohur et al., 2000),
these data are consistent with a postulated role for Dub-1 in the regulation of
IkBa stability.
Processing of Dub-1 but not Dub-2 through the UPP
The disappearance of Dub-1 protein following IL-3 starvation of FL5.12 cells
(Figure 2.4) indicated that Dub-1 may be targeted for degradation. Although the majority
of long-lived proteins are degraded through the lysosomal degradation pathway, many
short-lived proteins are degraded by the ubiquitin-proteasome pathway (UPP) (see
CHAPTER I). Therefore, experiments were performed to test whether Dub-1 is processed
through the UPP (Figure 2.5). First, experiments were performed to determine whether
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inhibition of the proteasome would result in the accumulation of endogenous Dub-1
protein. FL5.12 cells were treated with the proteasome inhibitor MG-132 or with DMSO
for 10 hours, and immunoanalyses were performed on the cell lysates using an antibody
to the carboxyl terminus of Dub-1 (Figure 2.5 – panel A). These results demonstrated that
Dub-1 is stabilized by MG-132 in FL5.12 cells. Similar results were obtained when cells
were treated with the proteasome inhibitor lactacystin (data not shown). Additional
experiments were performed to determine whether exogenous Dub-1 protein, expressed
in HEK-293T cells by transient transfection, would be stabilized by proteasome
inhibition (Figure 2.5 – panel B). Immunoanalyses of lysates of HEK-293T cells
overexpressing Dub-1 that were treated for 8 hours with MG-132 (lane 5) or with DMSO
(lane 4) indicated that exogenous Dub-1 was stabilized by inhibition of the proteasome.
To confirm that Dub-1 was degraded directly by the UPP, experiments were performed to
test whether Dub-1 was polyubiquitinated (Figure 2.5 – panel C). HEK-293T cells were
cotransfected with expression vectors encoding Dub-1 and HA-ubiquitin, followed by
treatment with MG-132 (lane 8) or DMSO (lane 7). Immunoanalyses of the anti-HA
immune complexes using an antibody to the carboxyl terminus of Dub-1 revealed
multiple high molecular weight proteins, consistent with the appearance of a Dub-1 poly
HA-ubiquitin “ladder.” Taken together, these experiments indicated that Dub-1 is
polyubiquitinated and degraded through the UPP
In contrast to Dub-1, exogenous Dub-2 was not degraded by the UPP. Exogenous
Dub-2 was not stabilized by MG-132 in HEK-293T cells (Figure 2.5 – panel B, compare
lanes 8 and 9), and polyubiquitinated Dub-2 was not observed in anti-HA immune
complexes from MG-132 treated HEK-293T cells overexpressing HA-ubiquitin and Dub-
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2 (Figure 2.5 – panel C, lanes 11 and 12). The observation that one member of the Dub-1
family (Dub-1) but not another member (Dub-2) is degraded through the UPP was
unexpected, given the amino acid similarities of the Dub-1 and Dub-2 proteins (Figure
1.5). The most obvious difference between these amino acid sequences is the presence of
two “hypervariable” (HV) repeat regions in the carboxyl terminus of Dub-1, as opposed
to three HV repeats in the corresponding region of Dub-2 (Figure 1.5). Therefore, it is
possible that the difference in stability of Dub-1 and Dub-2 is due to the different number
of HV regions in these proteins. However, the function(s) of the HV repeat regions
remains unknown. One possibility is that the HV regions mediate the stability of Dub
proteins by regulation of Dub binding to the ubiquitination machinery. Another
possibility is that the HV region may regulate the subcellular localization of Dub proteins
and thereby regulate degradation through the UPP in an indirect manner. For example,
the different number of HV repeat regions in Dub-1 versus Dub-2 could result in
differential nuclear and cytoplasmic localizations of these two proteins and thus
indirectly result in differential accessibility of these proteins to the degradation
machinery. This possibility is suggested based on the homology of the HV region to a
nuclear localization sequence present in c-myc (Dang and Lee, 1988; Hodel et al., 2001;
Makkerh et al., 1996; Post et al., 2001) (Figure 1.5 – panel B). However, preliminary
experiments indicated that the nuclear and cytoplasmic distribution of exogenous Dub
proteins is similar for Dub-1 and Dub-2 (data not shown; see also Figure 4.6 – panel A).
Additional experiments will be needed to elucidate why Dub-1 but not Dub-2 is degraded
by the UPP.
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I also tested whether Dub-1 catalytic activity influences degradation through the
UPP. One possibility is that Dub proteins may transfer ubiquitin from their substrates to
lysine residues within the Dub protein, thus targeting Dub for degradation by the 26S
proteasome. In this manner, Dub proteins would act in a “suicide” fashion during
substrate deubiquitination. This hypothesis was suggested by the presence of a lysine-rich
region near the Dub carboxyl terminus (Figure 1.5 – panel A) that might serve as ligation
sites for ubiquitin transferred from a substrate to Dub itself (Alan D’Andrea, personal
communication). One would predict that polyubiquitination of Dub-1 via this mechanism
would require Dub-1 catalytic activity. Since mutation of the active site cysteine of Dub-
1 to serine (C60S) abolishes Dub-1 deubiquitinating activity (Zhu et al., 1996), I tested
whether Dub-1 (C60S) is degraded through the UPP in HEK-293T cells using the same
experimental strategy that was used to demonstrate degradation of wild type Dub-1
through the UPP. These experiments demonstrated that mutant Dub-1, like the wild type
protein, was stabilized by MG-132 in HEK-293T cells (Figure 2.5 – panel B, compare
lanes 6 and 7). Furthermore, Dub-1 (C60S) was polyubiquitinated to a similar extent as
the wild type protein (panel C, compare lanes 8 and 10). These findings indicate that an
intact cysteine 60 is not required for degradation of Dub-1 through the UPP in HEK-293T
cells, and argue against the hypothesis that Dub-1 acts in “suicide” fashion during protein
deubiquitination. However, since the substrate(s) of Dub proteins has not been identified,
this hypothesis is difficult to test directly. It may be possible that Dub-1 acts in “suicide”
fashion to transfer ubiquitin from a substrate to itself, but a second, substrate-independent
pathway may also exist for the constitutive ubiquitination and degradation of Dub-1 in
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HEK-293T cells. The identification of substrate(s) for Dub proteins will help answer
these questions.
Discussion
In this chapter, I present an analysis of c-rel and dub-1 mRNA expression in the
embryo and of IL-3-regulated expression of dub-1 mRNA and Dub-1 protein in FL5.12
pro-B cells. These studies make use of a riboprobe corresponding to the 3’ end of the
dub-1 ORF and an antibody directed against the carboxyl terminus of Dub-1. This
antibody was also used in experiments to demonstrate that Dub-1 but not Dub-2 is
constitutively degraded through the UPP in HEK-293T cells. Furthermore, my findings
show that degradation of Dub-1 by the UPP does not require the active site cysteine of
Dub-1, thus arguing against the hypothesis that Dub-1 acts in “suicide” fashion during the
deubiquitination of protein substrates. These reagents will be useful for future
investigations of Dub-1 and Dub-2.
The overlapping expression patterns of dub-1 and c-rel mRNA in the developing
limb bud, as well as the correlation between Dub-1 expression and IkBa stability in
FL5.12 cells following IL-3 starvation, are consistent with a possible role for Dub-1 in
the regulation of the NF-kB signal transduction pathway. These observations provided
motivation for the development of an assay for the deubiquitination of IkBa, which is
presented in CHAPTER III. An examination of a potential role for Dub proteins in
regulation of the NF-kB pathway is presented in CHAPTER IV.
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CHAPTER III
IN VITRO DEUBIQUITINATION OF IkBa
Introduction
The ubiquitin-proteasome pathway (UPP) is the principal mechanism for the
selective degradation of short-lived proteins (Ciechanover, 1998; Hershko et al., 2000;
Hochstrasser, 1996; Pickart, 2000). The proximal signal for protein degradation via the
UPP is the post-translational conjugation to ubiquitin, a highly conserved, 76 amino acid
polypeptide. Ubiquitin conjugation is ATP-dependent and is achieved by the sequential
actions of members of three enzyme families: E1, or ubiquitin activating enzymes; E2, or
ubiquitin conjugating enzymes; and E3, or ubiquitin ligating enzymes. These enzymes
form an isopeptide bond between the carboxyl-terminal carboxylate of ubiquitin and the
e-amino group of a lysine residue in the target protein. Additional ubiquitin molecules are
attached in similar fashion to lysine residues of the first ubiquitin, and multiple rounds of
conjugation result in the formation of branched polymeric ubiquitin chains or “ladders.”
Polyubiquitinated proteins are then unfolded and degraded by the 26S proteasome, a
multicatalytic, multisubunit, ATP-dependent protease (Orlowski and Wilk, 2000). The
list of proteins processed through the UPP is long and includes cell cycle regulators,
transcriptional activators and inhibitors, cell surface receptors, and damaged or misfolded
proteins (Ciechanover et al., 2000). A wide variety of cellular functions are therefore
controlled by the UPP, including proliferation, differentiation, programmed cell death,
and antigen presentation (Voges et al., 1999). The obvious necessity for tight regulation
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of the UPP is underscored by its energy-rich, multistep mechanism of action. However,
the precise methods of regulation of the UPP are not fully understood.
Ubiquitination, like phosphorylation, is reversible. Protein phosphorylation is
controlled by the opposing activities of kinases and phosphatases. In an analogous
manner, the ubiquitination state of a protein is thought to be regulated by both
ubiquitinating and deubiquitinating enzymes. Protein deubiquitination occurs via the
hydrolysis of the isopeptide bond at the carboxyl terminus of ubiquitin (D'Andrea and
Pellman, 1998; Wilkinson, 2000). In contrast to ubiquitination, much less is known about
deubiquitination. Deubiquitinating enzymes are cysteine proteases and are divided by
sequence homology into two families, the ubiquitin carboxyl-terminal hydrolases (UCH)
and the ubiquitin-specific processing proteases (UBP) (Chung and Baek, 1999).
Functions of protein deubiquitination include the disassembly of unanchored
polyubiquitin chains, regeneration of ubiquitin after protein processing by the
proteasome, and trimming or removal of the protein polyubiquitin ladder (Wilkinson,
1997). In addition, deubiquitinating enzymes are required to generate active ubiquitin
monomers from proubiquitin gene products, which take the form of either a single amino-
terminal copy of ubiquitin fused to a ribosomal protein (Finley et al., 1989), or a fusion of
multiple ubiquitin monomers appended head-to-tail (Ozkaynak et al., 1984). These latter
proproteins contain short carboxyl-terminal peptide extensions that also must be removed
by deubiquitination to form active ubiquitin.
A wide variety of natural and engineered substrates have been used to examine
the specificities of deubiquitinating enzymes. These substrates include ubiquitin ethyl
ester (Wilkinson et al., 1986), ubiquitin 7-amido-4-methylcoumarin (Ub-AMC) (Dang et
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al., 1998), ubiquitin-b-galactosidase fusion proteins (Zhu et al., 1996), ubiquitin-
oligopeptide fusion proteins (Liu et al., 1989), proubiquitin gene products (Larsen et al.,
1998), and unanchored polyubiquitin chains (Wilkinson et al., 1995). Members of the
UCH family are postulated to cleave small adducts, such as peptides or amino acids, from
ubiquitin. In contrast, members of the UBP family are thought to target larger molecules
such as ubiquitinated proteins (D'Andrea and Pellman, 1998). However, the specificities
of deubiquitinating enzymes toward polyubiquitinated proteins are poorly understood.
Nevertheless, several observations support the concept that the functions of
deubiquitinating enzymes may extend beyond purely “housekeeping” purposes to include
more specialized roles. These observations include i) the relatively large number of
deubiquitinating enzymes as compared to the components of the ubiquitination
machinery, suggesting distinct roles for individual deubiquitinating enzymes
(Hochstrasser, 1996); ii) the large and highly divergent amino- or carboxyl-terminal
extensions found in many UBP enzymes, which may mediate specialized functions
(Wilkinson, 1997); iii) the highly specific and regulated expression patterns of many
UBP and UCH family members (Chung and Baek, 1999); and iv) mutational analyses
that reveal specific functions for several deubiquitinating enzymes (Wilkinson, 2000).
Recently, several UBPs have been proposed to mediate stabilization of particular
polyubiquitinated protein substrates via trimming or removal of the polyubiquitin
degradation signal. For example, the UBP family member Fat Facets has been proposed
to deubiquitinate and stabilize Liquid Facets in the Drosophila compound eye (Cadavid
et al., 2000; Huang et al., 1995; Wu et al., 1999). In addition, the murine UBP family
member UBPy has been proposed to deubiquitinate and stabilize the Ras guanine
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nucleotide exchange factor CDC25Mm (Gnesutta et al., 2001). However, these conclusions
have not been tested biochemically. In general, few direct analyses have been performed
to ascertain the specificities of deubiquitinating enzymes toward individual
polyubiquitinated proteins. Thus, it remains to be determined whether protein
deubiquitination, like protein dephosphorylation, may modulate signal transduction
through the deubiquitination of a specific regulator in the cascade.
Signal transduction via the nuclear factor-kappa B (NF-kB) family of
transcription factors is an excellent model system for studying the UPP. NF-kB plays
crucial roles in the regulation of many cellular processes including proliferation,
differentiation, and programmed cell death (Karin and Ben-Neriah, 2000; May and
Ghosh, 1998). NF-kB transcriptional activity is regulated principally by the inhibitory
kappa B (IkB) family of proteins, whose functions include binding and retention of NF-
kB dimers in an inactive state in the cytoplasm. In response to diverse stimuli, IkB is
sequentially phosphorylated, polyubiquitinated, and degraded by the 26S proteasome,
thus allowing NF-kB to enter the nucleus and modulate gene transcription. Signal-
dependent IkB phosphorylation is mediated by the IkB kinases 1 and 2 (IKK1 and IKK2),
which phosphorylate IkBa on serine residues 32 and 36 (Zandi and Karin, 1999).
Phosphorylated IkBa is then polyubiquitinated at lysine residues 21 and 22 by the
recently characterized SCFb-TrCP ubiquitin ligase, a multiprotein complex containing Skp1,
Cul1, and the F-box protein FWD1/b-TrCP (Maniatis, 1999).
In this report, I describe the isolation of polyubiquitinated, serine phosphorylated
IkBa from intact cells and the utilization of this substrate to measure deubiquitinating
activities in cellular extracts. My findings provide the first direct indication of an IkBa-
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directed deubiquitinating activity. Furthermore, the methods described herein may be
extended to the development of similar assays for monitoring the deubiquitination of
proteins other than IkBa. These assays will be extremely useful for determining the
functions and substrate specificities of deubiquitinating enzymes.
Materials and Methods
Chemicals
N-acetyl-L-cysteine (NAC), phenylmethylsulfonyl fluoride (PMSF), N-
ethylmaleimide (NEM), iodoacetamide, and bovine serum albumin (BSA) were obtained
from Sigma (St. Louis, MO) and added fresh to buffers as needed. Ubiquitin aldehyde
(Ub. Al.), ubiquitin 7-amido-4-methylcoumarin (Ub-AMC), ubiquitin C-terminal
hydrolase-L3 (UCH-L3), and MG-132 were purchased from Boston Biochem (Boston,
MA). Recombinant human tumor necrosis factor alpha (TNFa) was purchased from R&D
Systems (Minneapolis, MN).
Cell lines and culture
M12 (murine B lymphocyte) cells were the gift of Dr. Eugene Oltz (Vanderbilt
University) and were cultured at 370C/5% CO2 in RPMI 1640 (Mediatech, Inc., Herndon,
VA) supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100
IU/ml penicillin, 100 mg/ml streptomycin, and 50 mM b-mercaptoethanol. HeLa (human
epithelial) cells and HEK-293T cells (human embryonic kidney epithelial cells
expressing the SV40 large T antigen) were cultured at 370C/5% CO2 in Dulbecco’s
71
modified Eagle medium (Mediatech, Inc.) supplemented with 10% heat inactivated fetal
calf serum, 2 mM L-glutamine, 100 IU/ml penicillin, and 100 mg/ml streptomycin.
Antibodies
Anti-HA Affinity Matrix (immobilized rat monoclonal antibody, clone 3F10) was
purchased from Roche (Indianapolis, IN), and HA mouse monoclonal antibody HA.11
(clone 16B12) was purchased from BabCo (Richmond, CA). IkBa carboxyl terminus
rabbit polyclonal antibody (sc-371) was purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). T7-Tag mouse monoclonal antibody was purchased from Novagen
(Madison, WI). The horseradish peroxidase (HRP) conjugated secondary antibodies (goat
anti-rabbit Ig(H+L) and goat anti-mouse IgG1) were purchased from Southern
Biotechnology Associates, Inc. (Birmingham, AL).
Mammalian expression vectors
The T7-IkBa plasmid, which encodes human IkBa with an amino-terminal T7 tag
(Novagen, Madison, WI), was a gift from Dr. Dean Ballard (Brockman et al., 1995;
Scherer et al., 1995). The HA-ubiquitin plasmid, the Flag-IKK2 plasmid, and the Flag-
FWD1 plasmid were gifts from Dr. Mathias Treier (Treier et al., 1994), Dr. Frank
Mercurio (Mercurio et al., 1997), and Dr. Kei-ichi Nakayama (Shirane et al., 1999),
respectively.
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Preparation of poly HA-ubiquitinated T7-IkBa substrate for deubiquitination assays
HEK-293T cells were transiently cotransfected with T7-IkBa, HA-ubiquitin,
Flag-IKK2, and Flag-FWD1 mammalian expression vectors (2.5 mg of each plasmid per
10-cm dish) by calcium phosphate precipitation and glycerol shock (Sambrook et al.,
1989). Forty-eight hours post-transfection, cells were preincubated with MG-132 (40 mM)
for one hour and then with TNFa (20 ng/ml) for 15 minutes. Cells were thoroughly
washed in ice-cold phosphate buffered saline (PBS) and lysed in ice-cold Lysis Buffer A
that included Buffer C (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Triton-X-100, and
0.2% NP-40) supplemented with fresh protease inhibitors (1 mg/ml pepstatin, 3 mg/ml
aprotinin, 20 mM leupeptin, 1 mM PMSF, 1 mM EGTA, and 1 mM EDTA), phosphatase
inhibitors (10 mM sodium pyrophosphate, 10 mM NaF, and 0.4 mM sodium
orthovanadate), and 5 mM NEM (for inhibition of endogenous deubiquitinating
enzymes). Cell lysates were centrifuged at 15,000 x g at 40C for 10 minutes and the pellet
was discarded. Protein concentration of the clarified lysates was determined using the DC
Protein Assay kit (Bio-Rad Laboratories, Hercules, CA). Lysates were diluted to 2 mg/ml
in Lysis Buffer A, and immunoprecipitation was performed using 12 ml of a 50% slurry
of anti-HA resin per mg of cell lysate protein. The immune complexes were washed five
times in Lysis Buffer A and five times in Reaction Buffer A (Buffer C supplemented with
5 mM DTT, 1% BSA, phosphatase inhibitors, and protease inhibitors minus leupeptin). It
was typically necessary to readjust the pH of Lysis Buffer A and Reaction Buffer A to
7.5 after all components were added.
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Preparation of cell lysates for analysis of deubiquitinating activity
For preparation of M12 cell lysates used as a source of deubiquitinating activity,
cells were washed three times in ice-cold PBS and lysed in ice-cold Lysis Buffer B
(Buffer C supplemented with 1 mM DTT, phosphatase inhibitors, and protease inhibitors
minus leupeptin). Lysates were centrifuged at 15,000 x g at 40C for 10 minutes and the
pellet was discarded. Aliquots of the clarified lysates were snap-frozen in liquid nitrogen
and stored at -800C. Protein concentration was determined using the DC Protein Assay kit
(Bio-Rad Laboratories, Hercules, CA). Approximately 15 minutes prior to use in
deubiquitination reactions, lysates were diluted to 5-10 mg/ml in Lysis Buffer B, and
DTT was added to a final concentration of 5 mM. For heat inactivation, lysates were
heated to 950C for two minutes and placed back on ice. For chemical inactivation, lysates
were incubated for 15 minutes on ice with ubiquitin aldehyde (15 mM), NEM (15 mM),
iodoacetamide (15 mM), or MG-132 (120 mM). For reactions containing NEM or
iodoacetamide, the preincubation was allowed to proceed with only 1 mM DTT to avoid
reduction of the chemical inhibitor. Final reaction concentrations (after addition of
substrate) were 5 mM ubiquitin aldehyde, 5 mM NEM, 5 mM iodoacetamide, or 40 mM
MG-132.
For preparation of HeLa cell lysates used as a source of deubiquitinating activity,
HeLa cells were mock treated or incubated with NAC (30 mM) for one hour followed by
stimulation with TNFa (20 ng/ml) for 15 minutes. Lysates were  prepared for
immunoanalysis and deubiquitination assays as described above for M12 cells.
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Deubiquitination of IkBa
To assay the ability of M12 cell lysates to deubiquitinate IkBa, 10 ml of M12 cell
lysates (5-10 mg/ml) were added to 20 ml of the substrate (15% slurry of anti-HA matrix-
protein complexes in Reaction Buffer A) and incubated at 370C for one hour. Reactions
were terminated by the addition of 7.5 ml of 5x SDS sample buffer followed by a two
minute heat denaturation at 950C. Reaction products were detected by Western analysis
using IkBa antibodies.
Hydrolysis of Ub-AMC
Assays for hydrolysis of Ub-AMC by M12 cell lysates and UCH-L3 were
performed essentially as described (Dang et al., 1998). Reaction progress was monitored
over a period of 400 seconds using a SPEX 1681 0.22m spectrometer; the increase of
flourescence intensity at 460 nm (lex = 380 nm) was an indication of the hydrolysis of
Ub-AMC. A reaction cuvette (1 ml) containing 170 ml of Reaction Buffer B (20 mM Tris-
HCl, pH 7.5, 0.1% BSA, 0.5 mM EDTA, and 10 mM DTT) was placed in the
spectrometer, and readings were initiated. Approximately 90 seconds later, 10 ml of Ub-
AMC (0.04 mg/ml in DMSO) were added to the reaction, followed at approximately 240
seconds by the addition of 20 ml of either UCH-L3 (final concentration, 200 pM) or M12
cell lysates (final protein concentration, 20 mg/ml).
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Results
Generation of substrate for deubiquitination assays
I sought to establish an in vitro assay for the deubiquitination of IkBa.
Polyubiquitinated IkBa, isolated from mammalian cells, was used as the substrate. HEK-
293T cells were transiently cotransfected with mammalian expression vectors encoding
HA-ubiquitin, T7-IkBa, Flag-IKK2, and Flag-FWD1. Flag-IKK2 was included to
enhance phosphorylation of IkBa (Zandi and Karin, 1999). FWD1/b-TrCP binds directly
to serine 32-phosphorylated IkBa and is a component of the IkBa ubiquitin ligase
complex that catalyzes IkBa ubiquitination (Maniatis, 1999). To enrich the levels of
polyubiquitinated IkBa, cells were exposed to the proteasome inhibitor MG-132 (40 mM)
for one hour followed by TNFa (20 ng/ml) for 15 minutes, and then lysed. N-
ethylmaleimide (NEM), an alkylating reagent that inhibits the activities of many
deubiquitinating enzymes, presumably through alkylation of the active site cysteine
(Wilkinson, 1997), was included in the cell lysis buffer. A wide range of phosphatase and
protease inhibitors, including the cysteine protease inhibitor leupeptin, were also included
in the cell lysis buffer. Polyubiquitinated proteins were immunoprecipitated from cell
lysates using anti-HA beads. To visualize poly HA-ubiquitinated T7-IkBa, HA immune
complexes were analyzed by immunoblotting using antibodies specific for the carboxyl
terminus of IkBa or for the amino-terminal T7 tag (Figure 3.1 - left and middle panels).
In transfected cells, poly HA-ubiquitinated T7-IkBa was detected as high molecular
weight proteins whose levels were elevated upon treatment with MG-132 and TNFa
(compare lanes 2 to 3 and 5 to 6). To verify that these proteins were indeed poly HA-
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ubiquitinated T7-IkBa, cell lysates were subjected to immunoprecipitation using the IkBa
carboxyl terminus antibody and analyzed by immunoblotting with an HA antibody. A
similar pattern of protein expression was observed on these blots (Figure 3.1 – right
panel) as on the blots of the reciprocal immunoprecipitations (left and middle panels).
M12 cell lysates possess deubiquitinating activity
The product of the HA immunoprecipitations (Figure 3.1 - lane 3) was used as a
substrate of an in vitro assay to monitor IkBa deubiquitinating activity present in M12
cell lysates. M12 cells were lysed in a low-detergent buffer containing protease and
phosphatase inhibitors, taking care to omit any cysteine protease inhibitors such as
leupeptin, which might inhibit the activity of deubiquitinating enzymes. DTT was
included in the lysis and reaction buffers to maintain the reduced state of the active site
cysteine of deubiquitinating enzymes. To prevent nonspecific IkBa degradation, the
reaction buffer was supplemented with serine-, aspartate-, and metallo-protease
inhibitors. Phosphatase inhibitors were also included to prevent the deactivation of any
potential phosphorylation-dependent deubiquitinating activity. The deubiquitination
reaction was initiated by combining the HA immune complexes with M12 cell lysates.
After a one hour incubation at 370C, deubiquitination of T7-IkBa was monitored by
Western analysis of the reaction products using an IkBa carboxyl terminus antibody
(Figure 3.2).
Several control samples were included in these immunoanalyses so that the
identities of the IkBa isoforms could be established. Immunoblot analysis of the substrate
revealed high molecular weight poly HA-ubiquitinated T7-IkBa (lane 3). Endogenous
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Figure 3.1. Generation of polyubiquitinated IkBa as a substrate for
deubiquitination assays. HEK-293T cells were transiently cotransfected with either
vector controls or expression plasmids for T7-IkBa, HA-ubiquitin, Flag-FWD1, and
Flag-IKK2. After 48 hours, cells were incubated either with DMSO (-) or with 40 mM
MG-132 for one hour followed and then with 20 ng/ml TNFa (+) for 15 minutes. HA
immune complexes were isolated from the cell lysates and analyzed by immunoblotting
with IkBa carboxyl terminus (left panel) or T7 (middle panel) antibodies. For the
reciprocal experiment, immunoprecipitation was performed using IkBa carboxyl
terminus antibody, and immune complexes were analyzed by immunoblotting with HA
antibody (right panel). IP, immunoprecipitating antibody; IB, immunoblotting antibody.
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murine IkBa was observed in M12 cell lysates (lane 4). Endogenous human IkBa and
ectopically expressed T7-IkBa were detected by analysis of lysates from HEK-293T cells
overexpressing T7-IkBa (compare lanes 1 and 2). T7-IkBa typically appeared as a
doublet migrating more slowly than endogenous mouse or human IkBa. To determine the
phosphorylation status of T7-IkBa, lysates of T7-IkBa-transfected HEK-293T were
analyzed by immunoblotting with two different IkBa antibodies, one specifically
recognizing phosphorylated serine 32 and the other specifically recognizing
nonphosphorylated serine 32. These experiments indicated that the higher molecular
weight form of T7-IkBa was serine 32-phosphorylated, while the lower molecular weight
form was not serine 32-phosphorylated (data not shown). To determine the ubiquitination
status of T7-IkBa, a mutant version was expressed in which lysine residues 21 and 22
were mutated to arginine (K21/22R). Western analysis using the IkBa carboxyl terminus
antibody indicated that T7-IkBa (K21/22R) migrated at the same rate as T7-IkBa, thus
indicating that the ectopic T7-IkBa proteins were not ubiquitinated on these lysine
residues (data not shown).
Analysis of the deubiquitination reaction products (Figure 3.2, lanes 5 - 7)
revealed the presence of murine IkBa (from the M12 cell lysates) and poly HA-
ubiquitinated T7-IkBa (from the substrate). However, additional proteins were detected
in the reaction samples that were not seen in the substrate-only (lane 3) or the enzyme-
only (lane 4) samples. These proteins comigrated with the non-ubiquitinated T7-IkBa
doublet (lane 1). Increasing the concentration of M12 lysates resulted in a dose-
dependent increase in the levels of these proteins (compare lanes 5, 6, and 7). I interpret
these proteins as being T7-IkBa that was deubiquitinated by an activity present in the
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Figure. 3.2. Deubiquitination of IkBa by M12 cell extracts. M12 cell extracts (2, 0.2,
or 0.02 mg/ml final reaction concentrations in lanes 5, 6, or 7, respectively) were
incubated for one hour at 370C with HA immune complexes prepared as in Figure 3.1.
Western analysis of reaction products was performed with an IkBa carboxyl terminus
antibody. The relative migration rates of ectopic T7-IkBa and endogenous human and
mouse IkBa were visualized by immunoblot analysis of lysates (5 mg) from HEK-293T
cells transfected with (lane 1) or without (lane 2) T7-IkBa and by analysis of M12 cell
lysates (20 mg, lane 4). An aliquot of the HA immune complexes (substrate) was
analyzed in lane 3. The distortions in lanes 3 and 5 – 7 at the position of the asterisk
were due to the BSA included in the reaction buffer.
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M12 cell lysates. Stripping these membranes and reprobing them with an antibody to the
amino-terminal T7 tag confirmed the identity of these proteins as full-length T7-
IkBa (data not shown). To examine the phosphorylation status of deubiquitinated T7-
IkBa, membranes were stripped and reprobed with two antibodies, one specific for IkBa
phosphorylated on serine 32, and the other specific for non serine 32-phosphorylated
IkBa. These experiments revealed that the deubiquitinated T7-IkBa was phosphorylated
on serine 32 (data not shown). Similar activities were detected in reactions using FL5.12
(pro-B lymphocyte; see CHAPTER IV) lysates or HeLa (epithelial cell; data not shown)
lysates as the source of activity.
Specific inhibition of deubiquitinating activity in M12 cell lysates
To test whether the deubiquitinating activity present in M12 cell lysates was
sensitive to inhibitors of deubiquitinating enzymes, reactions were performed in which
the lysates were preincubated for 15 minutes on ice with various inhibitors (Figure 3.3).
Ubiquitin aldehyde is a specific inhibitor of many deubiquitinating enzymes (Hershko
and Rose, 1987; Shaeffer and Cohen, 1996). Alkylating reagents, such as N-
ethylmaleimide and iodoacetamide, also inhibit many deubiquitinating activities,
presumably through alkylation of the active site cysteine (Wilkinson, 1997). As expected,
preincubation with any one of these inhibitors reduced the level of deubiquitinating
activity (compare lanes 2, 4 and 6 to lanes 1 and 5). Likewise, pretreatment of M12
lysates with heat (950C for 2 minutes) inhibited the deubiquitinating activity (lane 3). In
contrast, preincubation of the lysates with MG-132, an inhibitor of the protease activities
of the proteasome, calpains, and cathepsins (Lee and Goldberg, 1998), did not have any
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Figure 3.3. Inhibition of IkBa deubiquitination by ubiquitin aldehyde, alkylating
reagents, or heat, but not by MG-132. A. M12 extracts were preincubated on ice for
15 minutes without (no inhibitor; lanes 1 and 5) or with ubiquitin aldehyde (lane 2), N-
ethylmaleimide (lane 4), iodoacetamide (lane 6), or MG-132 (lane 7), or were heated
for 2 minutes at 950C (lane 3). The treated lysates were then tested for their ability to
deubiquitinate IkBa as described in Figure 3.2. Each inhibitor was tested at least 3
times, and a representative experiment is shown. B. The levels of IkBa deubiquitination
in the experiment described in A were quantified by densitometry and graphed as the
percentage of activity relative to the control reaction (without inhibitor).
82
effect on the deubiquitinating activity (lane 7). The maintenance of activity in the
presence of a wide range of protease inhibitors (e.g., MG-132 and serine-, aspartate-, and
metallo-protease inhibitors), and the loss of activity in the presence of various inhibitors
of deubiquitinating enzymes (e.g., ubiquitin aldehyde, NEM,  or iodoacetamide) or heat
treatment, indicate that the activity detected in this assay was mediated by a member of
the deubiquitinating families of enzymes and was not due to nonspecific protease
activity.
Specificity of deubiquitination of IkBa 
To address the enzymatic specificity of IkBa deubiquitination, purified UCH-L3
was tested for its ability to deubiquitinate IkBa. UCH-L3 is a member of the ubiquitin
carboxyl-terminal hydrolase (UCH) family of deubiquitinating enzymes and is expressed
primarily in hematopoietic tissues (Wilkinson et al., 1992). UCH-L3 is enzymatically
active against a wide range of ubiquitin leaving groups (Larsen et al., 1998). To verify
that the UCH-L3 preparation used in these experiments was enzymatically active, UCH-
L3 was first tested for its ability to hyrolyze ubiquitin 7-amido-4-methylcoumarin (Ub-
AMC). The bond between the carboxyl terminus of ubiquitin and AMC is an isopeptide
bond, chemically identical to the bond cleaved by deubiquitinating enzymes. Cleavage of
AMC from ubiquitin results in an increase in its fluorescence, which can be measured
using a spectrophotometer. Thus, Ub-AMC has been utilized as a model substrate for
assaying deubiquitinating activities, including UCH-L3 (Dang et al., 1998). UCH-L3
exhibited significant deubiquitinating activity toward Ub-AMC (Figure 3.4 - panel A). In
a parallel experiment, M12 cell lysates, prepared in the same manner as used for the
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Figure 3.4. UCH-L3 does not deubiquitinate IkBa. A. UCH-L3 (200 pM) and M12
extracts (20 mg/ml) were tested for their ability to hydrolyze ubiquitin 7-amido-4-
methylcoumarin (Ub-AMC). Release of AMC from ubiquitin was detected as an
increase in flourescence intensity (arbitrary units) at 460 nm (lex = 380 nm) (y-axis) as a
function of time (x-axis). The rate of change of fluorescence (after both substrate and
enzyme have been added) was used as a measure of deubiquitinating activity. The
transient decreases in fluorescence during addition of substrate and enzyme were due to
the closure of the spectrometer detection shutter during the removal of the reaction
cuvette. A representative of 3 experiments is shown. B. UCH-L3 was tested for its
ability to deubiquitinate IkBa. M12 cell extracts (final concentration, 2 mg/ml) provided
the source of activity for the positive control reaction (lane 1). As a negative control, the
substrate was incubated in reaction buffer alone (lane 5). Reactions containing UCH-L3
were at final concentrations of 100, 10, or 1 nM (lanes 2, 3, and 4, respectively). A
representative of at least four independent experiments is shown in each panel.
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assays of deubiquitination of T7-IkBa, also hydrolyzed Ub-AMC (Figure 3.4 - panel A).
In these experiments, 200 pM UCH-L3 hydrolyzed Ub-AMC at roughly the same rate as
20 mg/ml of M12 lysates, indicating that these concentrations of UCH-L3 and M12
lysates contained comparable levels of deubiquitinating activity.
To test whether UCH-L3 could deubiquitinate IkBa, reactions were performed as
described in Figure 3.2 using a range of concentrations of UCH-L3 (Figure 3.4 - panel
B). In these experiments, M12 lysates (2 mg/ml) were used as a positive control (lane 1),
and cell lysis buffer alone was used as a negative control (lane 5). UCH-L3 demonstrated
no detectable activity towards poly HA-ubiquitinated T7-IkBa even at concentrations as
high as 100 nM (lane 2). This concentration of UCH-L3 is expected to contain
approximately five-fold more activity than 2 mg/ml of M12 cell lysates, based on the Ub-
AMC assay (panel A). These experiments indicate that UCH-L3 and M12 cell lysates
display different substrate specificities toward IkBa and Ub-AMC, and suggest some
degree of enzymatic specificity in the deubiquitination of IkBa.
Discussion
In this chapter, I have provided direct biochemical evidence for the presence of
deubiquitinating activity towards poly HA-ubiquitinated, serine 32-phosphorylated T7-
IkBa in the lysates of several cell types. Deubiquitinated T7-IkBa was the full length T7-
IkBa protein, given the fact that it was recognized by an amino-terminal T7 antibody and
an IkBa carboxyl terminus antibody. This activity was inhibited by heat and by inhibitors
of deubiquitinating enzymes (ubiquitin aldehyde or alkylation) but was unaffected by
MG-132, which inhibits proteolytic activity of the proteasome, calpains, and cathepsins,
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thus indicating that this activity was mediated by a member of the deubiquitinating
families of enzymes and was not due to nonspecific proteolysis. Although only a small
amount of substrate was deubiquitinated in these reactions, this amount was proportional
to the concentration of cell extracts included in the reaction (Figure 3.2), thus indicating
that this assay may be used to quantify deubiquitinating activity. For the subset of T7-
IkBa that was deubiquitinated, deubiquitination resulted in the removal of the entire
polyubiquitin ladder, resulting in a protein whose migration rate corresponded closely to
that of nonubiquitinated T7-IkBa. Whether the entire polyubiquitin ladder was removed
through a single cleavage of the IkBa-proximal isopeptide bond, or whether ubiquitin
monomers were removed one at a time from the distal end of the polyubiquitin chain, is
unclear. However, I favor the explanation that the entire ladder was removed in a single
cleavage event, based on preliminary kinetic studies using shorter reaction times that
failed to detect a transient appearance of anti-IkBa immunoreactive proteins of
intermediate molecular weight (data not shown).
Western analyses using antibodies specific to the serine 32-phosphorylated or
serine 32 non-phosphorylated forms of IkBa revealed that the deubiquitinated T7-IkBa
protein was phosphorylated on this residue (data not shown). In related experiments, I
also examined which lysine residue(s) of T7-IkBa was deubiquitinated. Of the nine
lysines present in human and mouse IkBa, signal-induced ubiquitination of NF-kB-bound
IkBa occurs primarily on lysines 21 and 22, presumably due to the fact that these lysines
are most accessible to the ubiquitination machinery (Scherer et al., 1995). The T7 tag was
chosen for these experiiments because it does not incorporate additional lysines into the
amino terminus of IkBa. I observed that overexpressed T7-IkBa (K21/22A), in which
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lysines 21 and 22 were substituted for alanine, could be poly HA-ubiquitinated, albeit to a
lesser extent than wild-type T7-IkBa (data not shown). However, when anti-HA immune
complexes containing polyubiquitinated T7-IkBa (K21/22A) were used as the substrate
of a deubiquitination assay, no deubiquitination was observed over background levels
(data not shown). Taken together, these data suggest that cell extracts contain an activity
capable of removing the entire polyubiquitin ladder from lysine residues 21 and/or 22 of
IkBa, phosphorylated on serine 32.
It is currently unknown whether this activity is constitutive or whether it may be
regulated in some manner. However, the data presented in this chapter are consistent with
the idea that deubiquitination of IkBa may “rescue” IkBa from degradation by the
proteasome. The current model of NF-kB activation is that IkBa degradation is regulated
principally at the level of serine phosphorylation by the IkB kinases (IKK) (Karin and
Ben-Neriah, 2000). In this model, activation of IKK results in phosphorylation of IkBa on
serines 32 and 36, followed by binding of the IkBa ubiquitin ligase machinery and
subsequent IkBa ubiquitination and degradation. However, there are instances in which
serine 32-phosphorylated IkBa is not degraded through the UPP. A recent report
examining the mechanism by which certain mutant Salmonella strains inhibited cytokine-
induced activation of NF-kB showed that exposure of cells to these mutant strains
resulted in accumulation of IkBa that was serine 32-phosphorylated but not
polyubiquitinated (Neish et al., 2000). One possible explanation of these observations is
that mutant strains induce the deubiquitination of IkBa, although an inhibition of IkBa
ubiquitination has not been ruled out.
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The identity(ies) of the enzyme(s) that deubiquitinates IkBa is unknown. UCH-L3
did not deubiquitinate IkBa (Figure 3.4). Analyses of the ability of Dub-1 and Dub-2 to
deubiquitinate IkBa are presented in CHAPTER IV. Using a somewhat different assay,
one group found that a bacterially expressed GST fusion of the Drosophila homologue of
UCH-L1 was able to deubiquitinate IkBa (Roff et al., 1996). However, these reactions
were performed using supraphysiologic (10 mM) concentrations of GST-UCH-L1, and it
is unknown whether this enzyme would demonstrate the same activity at physiologic
concentrations. The specificity of the enzyme(s) that deubiquitinates IkBa differs from
those of several other well-characterized deubiquitinating enzymes. Mutation of one
yeast UBP family member, ubp4/doa4, resulted in the appearance of small ubiquitinated
species and the depletion of intracellular pools of ubiquitin (Papa and Hochstrasser,
1993). Thus, doa4 is thought to function late in the UPP by recycling ubiquitin from
remnant peptides after protein degradation by the proteasome, and is unlikely to
hydrolyze polymeric ubiquitin from proteins. The yeast ubp14p and its human
homologue, isopeptidase T, hydrolyze unanchored polyubiquitin chains and presumably
work, like doa4, at the post-proteasomal level (D'Andrea and Pellman, 1998). Hydrolysis
by isopeptidase T proceeds sequentially from the proximal end of the ubiquitin chain and
is greatly inhibited by the presence of a protein or other modification at the carboxyl
terminus of the proximal ubiquitin (Wilkinson et al., 1995). Therefore, it is unlikely that
isopeptidase T mediates the deubiquitination of IkBa.
Several groups have described deubiquitinating activities that are tightly
associated with the 26S proteasome. While I have not directly tested whether proteasomal
preparations can deubiquitinate IkBa, the characteristics of these enzymes make this
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unlikely. One group has described an ATP-dependent activity associated with the 26S
proteasome that liberates ubiquitin from mono-ubiquitinated lysine residues of lysozyme
(Eytan et al., 1993). Since this activity is unaffected by ubiquitin aldehyde, it is different
from the IkBa-directed deubiquitinating activity described in this chapter. Another group
has described an isopeptidase “editing” activity present in the 19S regulatory complex of
the proteasome (Lam et al., 1997; Lam et al., 1997). According to one model, proposed
by Hershko et al. (Hershko et al., 1980) and elaborated on by Shaeffer and Cohen
(Shaeffer and Cohen, 1996), a low basal level of nonspecific protein deubiquitination
from the distal end of the polyubiquitin chain (away from the protein) would prevent
degradation of proteins modified by short ubiquitin oligomers, but not by large
polyubiquitin chains. Consistent with this model, the 19S-associated “editing”
isopeptidase disassembles the polyubiquitin chain sequentially from the distal end of the
chain. In contrast, I detect removal of the entire polyubiquitin chain from IkBa,
apparently in one step. Thus it is unlikely that the 19S-associated “editing” activity is the
one detected in the assay presented in this chapter.
The degree of functional specialization of deubiquitinating enzymes is not well
understood. This issue was addressed by mutational analysis of each of the 17
deubiquitinating enzymes in S. cerevisiae, 14 of which were active in vitro (Amerik et al.,
2000). Surprisingly, all mutants were viable, and most grew normally under standard
conditions. These results are consistent with the notion that there is some degree of
functional redundancy of deubiquitinating enzymes. On the other hand, some of these
enzymes may have highly specialized functions that are manifested only under particular
conditions. For example, Ubp15-deficient cells are sensitive to a variety of suboptimal
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growth conditions but have no obvious defect in overall ubiquitin metabolism, thus
suggesting a specialized function for this protein (Amerik et al., 2000). The situation may
be more complex in higher organisms. For example, genetic evidence exists to suggest
that the UBP family member, Fat Facets, regulates eye development in Drosophila
through deubiquitination and stabilization of Liquid Facets (Cadavid et al., 2000).
There are several potential reasons why deubiquitinating enzymes may work in
concert with the ubiquitination machinery to determine specificity of protein targeting to
the UPP. One function may be to construct a complex circuitry responsive to multiple
upstream signals. This could explain how an individual pathway, such as NF-kB, may be
regulated simultaneously by diverse stimuli. A second purpose of deubiquitination may
be to modulate protein half-life with rapid kinetics. This situation is analogous to that of
the phosphorylation system, in which the concerted action of kinases and phosphatases
acutely modulates the steady-state levels of protein phosphorylation. The quick response
of a cell to its environment is critical for the proper function of signaling cascades such as
NF-kB, which must respond rapidly to many stimuli. A third function of deubiquitination
may be to make exquisite adjustments of protein half-life. Recent evidence indicates that
the affinity of a polyubiquitinated protein to the proteasome, as well as the residence time
on the proteasome, is increased as the size of the polyubiquitin chain is increased
(Thrower et al., 2000). By “editing” the side chain of a polyubiquitinated protein from its
distal end, a deubiquitinating enzyme may fine-tune the rate of protein degradation
through the UPP. Experimental manipulation of such an activity may be expected to
produce phenotypes that are subtle and, therefore, difficult to detect. However, such a
mechanism might provide an explanation and justification for the high amount of energy
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spent by the cell in building a multipolymeric proteolytic signal in the first place (Pickart,
2000).
In summary, I have described an in vitro assay for studying IkBa deubiquitination
using poly HA-ubiquitinated serine 32-phosphorylated T7-IkBa as the substrate and
various cell lysates as the activity source. My results provide the first direct evidence of
an IkBa-directed deubiquitinating activity. This assay will be useful for studying the
mechanism of IkBa deubiquitination, including regulation of the deubiquitinating
activity, the role of IkBa deubiquitination in the control of NF-kB signaling, and the
identity of the deubiquitinating enzyme(s) responsible. Furthermore, these methods can
be easily modified to study the deubiquitination of other proteins, and will be useful for
elucidating the functions, regulation, and substrate specificities of deubiquitinating
enzymes.
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CHAPTER IV
DUB-1 AND DUB-2 DO NOT REGULATE THE NF-kB
SIGNAL TRANSDUCTION PATHWAY
Introduction
The experiments presented in this chapter were designed to test the hypothesis
that Dub-1 and Dub-2 modulate signal transduction through the NF-kB pathway. Several
observations provided the motivation for this hypothesis. First, Dub-1 expression
decreases in FL5.12 cells following interleukin-3 (IL-3) starvation (Figure 2.4), which
also results in a decrease in the levels of cytoplasmic IkBa, an increase in the levels of
nuclear c-Rel, and an increase in the levels of NF-kB transcriptional activity in FL5.12
cells (Sohur et al., 2000). Thus, Dub-1 expression may be positively correlated with
IkBa stability in pro-B lymphocytes. Second, dub-1 mRNA expression is highest during
the G1 phase of the cell cycle in FL5.12 pro-B cells (Zhu et al., 1996). Conversely, NF-
kB DNA-binding activity is lowest during the G1 phase of the cell cycle in 70Z/3 pre-B
cells (Kerr, unpublished data). These findings suggest that Dub-1 expression may be
inversely correlated with NF-kB activity during the cell cycle of early lineage B
lymphocytes. Third, c-rel and dub-1 mRNAs have overlapping patterns of expression in
the limb buds and pharyngeal arches of the mouse during embryogenesis (Figure 2.1),
consistent with a potential role for Dub-1 in the regulation of NF-kB. Based upon these
observations, I hypothesized that Dub-1 and Dub-2 might deubiquitinate IkBa and
thereby prevent IkBa degradation through the UPP. According to this hypothesis,
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increased activity of Dub-1 or Dub-2 would be associated with increased stability of
IkBa and therefore with decreased NF-kB activity.
Several complementary strategies were used to test this hypothesis. To test
whether polyubiquitinated IkBa is a direct substrate for Dub-1 and Dub-2, recombinant
Dub-1 and Dub-2 proteins were expressed and purified from E. coli and mammalian cells
and used in an in vitro deubiquitination assay with poly HA-ubiquitinated T7-IkBa as the
substrate (CHAPTER III). This assay was also used to test whether IkBa-directed
deubiquitinating activity correlates with endogenous Dub-1 protein levels in cell extracts.
To test whether Dub-1 and Dub-2 regulate IkBa stability indirectly (e.g. by
deubiquitination of a protein upstream in the NF-kB signaling pathway), I examined the
effect of Dub-1 and Dub-2 overexpression on the half-life of IkBa. Finally, to test
whether Dub-1 and Dub-2 regulate NF-kB signal transduction by an alternative
mechanism (that does not necessarily involve IkBa stability), I examined the effect of
Dub-1 and Dub-2 overexpression on NF-kB DNA-binding activity.
Materials and Methods
Chemicals
Lipopolysaccharide (LPS) E. coli serotype 055:B5 was purchased from Sigma (St.
Louis, MO). PMA and ionomycin were purchased from Calbiochem (San Diego, CA).
Glutathione and Glutathione Sepharose 4B were purchased from Amersham Pharmacia
Biotech (Piscataway, NJ).
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Plasmids
Mammalian expression vectors (pcDNA3-based) encoding wild type (WT)
murine Dub-1 and Dub-2, as well as pGEX–based plasmids used for expression of GST-
Dub-1 (WT and C60S) and GST-Dub-2 (WT and C60S) fusion proteins in E. coli, were
generous gifts from Dr. Alan D’Andrea (Zhu et al., 1996; Zhu et al., 1997).
Plasmids used for tetracycline-regulated expression
The dub-1 and dub-2 open reading frames (ORF) were amplified from pcDNA3-
Dub-1 and pcDNA3-Dub-2, respectively, by PCR using the following primers: 5’-
GCGAATTCTTTGAAGAGGTCTTTGGAGA-3’ (-19 to 1) (introducing a 5’ EcoRI site)
and 5’-ATCTCGAGGTGTCCACAGGAGCCTGTGT-3’ (1801 to 1781) (introducing a
3’ XhoI site). PCR products were blunt-end ligated into the pCR-Script plasmid
(Stratagene, La Jolla, California). The codon corresponding to cysteine 60 was converted
to a serine codon using the QuikChange Site-Directed Mutagenesis kit (Stratagene, La
Jolla, California) using the sense oligonucleotide 5’-
CAGAACACAGGGAATTCCTCCTACCTGAATGCAGCCCTGCAGTGC-‘3 and the
antisense oligonucleotide 5’-
GCACTGCAGGGCTGCATTCAGGTAGGAGGAATTCCCTGTGTTCTG-3’ according
to the manufacturer’s instructions. Dub-1 (WT and C60S) and dub-2 (WT)
complementary DNAs (cDNAs) were tagged with the S-Tag epitope by subcloning the
EcoRI/XhoI fragments of the pCR-Script-Dub constructs into the corresponding sites of
pCITE-4a(+) (Novagen, Madison, Wisconsin), in frame with the amino-terminal S-Tag
epitope. The MscI/BglII fragments of the pCITE-4a-based plasmids were subcloned into
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the PmeI/BglII sites of the pTR5-DC/GFP*-TK/hygro plasmid (Mosser et al., 1997) to
generate pTR5-S-Tag-Dub-1 (WT and C60S) and pTR5-S-Tag-Dub-2 (WT). All pTR5-
S-Tag-Dub plasmids were verified to conform to the predicted (published) sequences by
multiple restriction enzyme digests and by sequencing along the entire length of both
strands of the inserted regions.
Plasmids used for expression of 6xHis-Dub fusion proteins in mammalian cells
Dub-1 (WT and C60S) and dub-2 (WT and C60S) cDNAs were tagged with the
6x-His tag by subcloning the BamHI/XhoI fragments of the pCR-Script-Dub-1 and
pcDNA3-Dub-2 constructs into the corresponding sites of pcDNA3.1/His C (Invitrogen,
Carlsbad, CA), in frame with the amino-terminal 6xHis tag. All pcDNA3.1/His C-Dub
plasmid sequences were verified as described above for pTR5-Dub plasmids.
Expression and purification of GST-Dub fusion proteins from E. coli
The E. coli strain BL21 DE3 PlysS harboring pGEX-Dub-1 (WT or C60S) or
pGEX-Dub-2 (WT or C60S) plasmids were cultured in a 300C shaker. Protein expression
was induced by the addition of 0.1 mM isopropyl b-D-thiogalactoside (IPTG). One hour
post induction, bacteria were pelleted, rinsed in phosphate buffered saline (PBS), and
resuspended in ice-cold bacterial lysis buffer that included Buffer D (20 mM Tris-HCl,
pH 7.5, 2 mM dithiothreitol, 0.1% NP40, 0.05% Triton-X 100) supplemented with
protease inhibitors (1 mg/ml pepstatin, 3 mg/ml aprotinin, 1 mM PMSF, 1 mM EGTA, and
1 mM EDTA) and phosphatase inhibitors (10 mM sodium pyrophosphate, 10 mM NaF,
and 0.4 mM sodium orthovanadate). Following sonication (6 x 10-second bursts), the
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bacterial lysates were centrifuged and the resulting supernatants (17.5 ml per sample)
were incubated with 1 ml of a 50% slurry of Glutathione Sepharose 4B for 30 minutes on
ice. Proteins were washed five times in Buffer D and eluted with three separate 500 ml
washes of glutathione elution buffer (Buffer D supplemented with 1 mg/ml BSA and 10
mM glutathione). Glutathione was removed by dialysis (Slide-A-Lyzer, Pierce) against
Reaction Buffer A (see CHAPTER III). The dialyzed products were analyzed by
immunoblotting using an antibody to the carboxyl terminus of Dub-1, and tested for
deubiquitinating activity using the protocol outlined in CHAPTER III.
Expression and purification of 6xHis-Dub fusion proteins from HEK-293T cells
HEK-293T cells were transiently transfected with empty vector or with
mammalian expression vectors (10 mg DNA per 10-cm dish, 10 dishes per plasmid)
encoding 6xHis tagged Dub-1 (WT or C60S) or 6xHis tagged Dub-2 (WT or C60S) by
calcium phosphate precipitation and glycerol shock (Sambrook et al., 1989). Forty-eight
hours post-transfection, cells were thoroughly washed in ice-cold PBS and lysed in ice-
cold lysis buffer (20 mM Tris-HCl, pH 7.5, 0.1% NP40, 0.05% Triton-X 100, 1 mg/ml
pepstatin, 3 mg/ml aprotinin, 1 mM PMSF, 10 mM sodium pyrophosphate, 10 mM NaF,
0.4 mM sodium orthovanadate, and 5 mM b-mercaptoethanol). Cell lysates were
centrifuged at 15,000 x g for 10 minutes at 40C and the pellet was discarded. Clarified
lysates from each sample were incubated with 30 ml of a 50% slurry of nickel-NTA resin.
Bound proteins were washed five times in lysis buffer followed by five washes in lysis
buffer containing 10 mM imidazole (pH 7.5), and then eluted with three separate 50 ml
washes of lysis buffer supplemented with 100 mM imidazole (pH 7.5). Imidazole was
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removed by dialysis as described for the GST-fusion proteins (above), followed by the
addition of 5 mM dithiothreitol. The resulting products were assayed by immunoblotting
using an antibody to the amino-terminal Xpress epitope (Invitrogen, Carlsbad, CA), and
tested for deubiquitinating activity using the protocol outlined in CHAPTER III.
Tetracycline-regulated expression of Dub-1 and Dub-2 in M12 cells
The tetracycline system used in this dissertation was a hybrid of the original
system (Gossen and Bujard, 1992) that was subsequently modified (Shockett et al.,
1995). The inducible tetracycline repression system utilizes components of the bacterial
Tet operon system (Figure 4.1). Two constructs dictate inducible expression of the gene
of interest. Plasmid pTR5 places the gene of interest under the control of a promoter
containing the tetracycline operator sequence (tetO). Plasmid pTET-tTak generates a
fusion protein, the tetracycline transactivator (tTA), which is also under the control of
tetO. The tetracycline transactivator tTA is a fusion protein consisting of TetR and the
viral transactivator, VP16. In the absence of tetracycline, tTA binds the tetO cis-element
with high affinity and stimulates transcription of tTA and the gene of interest. When
tetracycline is present, tTA is reversibly bound and transcriptional activation of tTA and
the gene of interest do not occur.
The S-Tag-Dub-1 (WT and C60S) and S-Tag-Dub-2 (WT) inducible cell lines
were generated by cotransfection of linearized pTET-tTAk (GibcoBRL), pPGKPuro, and
the pTR5 empty vector or the pTR5-based plasmid encoding either S-Tag-Dub-1 (WT),
S-Tag-Dub-2 (WT), or S-Tag-Dub-1 (C60S) into the murine B cell line M12. Transfected
cells were selected in RPMI 1640 medium supplemented with 10% fetal calf serum, 2
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mM L-glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin, 50 mM b-
mercaptoethanol, 500 ng/ml tetracycline, and 1 mg/ml puromycin. Approximately 1 – 2
weeks post selection, individual puromycin-resistant clonal populations were titrated with
large-bore sterile pipet tips, expanded, and screened by flow cytometry (Flowstar,
Becton-Dickinson) for tetracycline-regulated GFP activity. Inducible clones were further
screened by immunoanalysis using S-Protein-HRP conjugate (Novagen, Madison, WI) or
using an antibody to the Dub-1 carboxyl terminus (see CHAPTER II).
Deubiquitination of IkBa
Deubiquitination assays were performed essentially as described in CHAPTER
III. Assays of FL5.12 cell lysates were performed using 2.5 mg/ml cell lysates. Assays of
purified 6xHis-Dub proteins were performed in a 30 ml reaction volume using purified
product that corresponded to an input of 4.5 mg of HEK-293T crude lysate. Assays of
purified GST-Dub proteins were performed in a 30 ml reaction volume using purified
product that corresponded to an input of 2.3 mg of bacterial crude lysate.
Measurement of IkBa half-life
Tetracycline-regulated M12 cells were induced to express Dub proteins by
removal of tetracycline from the cell culture media. Twenty-four hours after induction,
protein synthesis was inhibited by the addition of cycloheximide (10 mg/ml) to the cell
culture media. Ten minutes later, cells were stimulated with LPS (20 mg/ml) or were left
unstimulated and then harvested at 0, 1, 2, or 4 hours after the addition of LPS. Cells
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were washed in ice-cold PBS, lysed in lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 0.2% SDS, 0.1% Triton-X-100, 0.2% NP-40, 1 mg/ml pepstatin, 3 mg/ml aprotinin,
20 mM leupeptin, 1 mM PMSF, 1 mM EGTA, 1 mM EDTA, 10 mM sodium
pyrophosphate, 10 mM NaF, and 0.4 mM sodium orthovanadate), and centrifuged at
15,000 x g for 10 minutes at 40C. After determination of the protein concentration (DC
Protein Assay Kit, Bio-Rad Laboratories, Hercules, CA), the cell lysates were analyzed
by immunoblotting using an antibody to the IkBa carboxyl terminus. Equal protein
loading was confirmed by staining the membranes with Ponceau S Red prior to
immunoblot analysis.
Electrophoretic mobility shift assays (EMSA)
M12 cells were induced to express Dub proteins by 12 hour tetracyaline
withdrawal, and then cultured in low serum medium (0.5% FCS) for 18 hours, followed
by stimulation with LPS (20 mg/ml) or PMA (1 mM) plus ionomycin (1 mM) for one hour.
Cells were pelleted by centrifugation at 1000 x g for 5 minutes, washed in ice-cold PBS,
repelleted, and solubilized in lysis buffer (10 mM Hepes, pH 7.9, 10 mM KCl, 0.1 mM
EDTA, 0.1 mM EGTA, 0.4% NP-40, 1 mM dithiothreitol, 0.5 mM PMSF, 3 mg/ml
aprotinin, 1 mg/ml pepstatin, and 0.4 mM sodium orthovanadate). Nuclei were isolated by
centrifugation at 2000 x g for 5 minutes and the supernatant (cytoplasmic fraction) was
removed. Nuclear extracts were prepared from the pelleted nuclei by extraction (20 mM
Hepes, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 1 mM
PMSF, 3 mg/ml aprotinin, 1 mg/ml pepstatin, and 0.4 mM sodium orthovanadate) and
centrifugation at 15,000 x g for 10 minutes. Protein concentration was determined using
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the DC Protein Assay kit (Bio-Rad Laboratories, Hercules, CA). DNA binding reactions
were performed on nuclear extracts as described previously (Petro et al., 2000) using a
32P-labelled oligonucleotide probe corresponding to an NF-kB binding site present in the
k light chain enhancer (Promega, Madison, WI) (Sen and Baltimore, 1986). Competition
assays were performed using 50 x molar excess of unlabelled wild type probe or mutated
oligonucleotide (Promega, Madison, WI). Briefly, DNA binding reactions were
performed in a 20 ml reaction volume containing 20 mM HEPES, pH 7.9, 50 mM KCl, 1
mM EDTA, 1% NP-40, 5% glycerol, 1 mg/ml BSA, 2 mg double-stranded poly(dI-dC), 2
mg random nonamer, 10 mM dithiothreitol, 1 ml (50,000 – 100,000 cpm) of 32P-labelled
probe, and 20 mg of nuclear proteins. After a 15 minute incubation on ice, DNA-
nucleoprotein complexes were resolved on native 5% polyacrylamide gels and visualized
by autoradiography.
Results
Partially purified Dub-1 and Dub-2 do not deubiquitinate IkBa 
To determine whether either of the Dub proteins could deubiquitinate IkBa,
6xHis-tagged Dub-1 and Dub-2 proteins were expressed and purified from HEK-293T
cells and tested for their ability to deubiquitinate polyubiquitinated IkBa (see
MATERIALS AND METHODS). Immunoanalysis using an antibody recognizing the
amino-terminal Xpress epitope of the 6xHis-Dub proteins was used to examine
expression of proteins in crude HEK-293T extracts (Figure 4.2 – panel A, lanes 1 – 5)
and to assess the levels of protein obtained following purification on nickel-NTA beads
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Figure 4.2. Inability of 6xHis-Dub-1 and 6xHis-Dub-2 to deubiquitinate IkBa. A. HEK-
293T cells were transiently transfected with vector control (lane 5) or mammalian expression
vectors for 6xHis-Dub-1 (wild type, lane 1; C60S, lane 2) or 6xHis-Dub-2 (wild type, lane 3;
C60S, lane 4). Cell lysates were incubated with nickel agarose beads followed by protein
elution with imidazole and dialysis against deubiquitination reaction buffer (lanes 6 - 10).
Aliquots of the cell lysates (75 mg) and enriched proteins (corresponding to 1 mg input of crude
lysates) were analyzed by immunoblotting using an antibody to the amino-terminal Xpress
epitope (top panel). The migration of Dub-1 was slightly distorted because BSA was included
as a stabilizer in the purification process. The purity of the enriched samples was analyzed by
staining the membranes with Ponceau S Red prior to immunoblot analysis (bottom panel). B.
Enriched proteins (corresponding to 4.5 mg input of crude lysate) were tested for their ability
to deubiquitinate IkBa. M12 cell extracts (final concentration, 2 mg/ml) provided the source of
activity for the positive control reaction (lane 1). Reactions were performed using the indicated
wild type (lanes 3, 4, 6, and 7) and mutant (lanes 5 and 8) Dub proteins that had been
preincubated without (lanes 3, 5, 6, and 8) or with (lanes 4 and 7) ubiquitin aldehyde (Ub. Al.).
Substrate incubated with reaction buffer alone is indicated as “mock” reaction (lane 2).
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 (lanes 6 – 10). Expression of all four proteins was detected in crude extracts, with 6xHis-
Dub-2 being the most highly expressed (lanes 1 – 4). All four proteins were recovered
from nickel-NTA beads (lanes 6 – 9), although only low levels of 6xHis-Dub-1 proteins
were detected (lanes 6 and 7). The 6xHis-Dub-1 proteins may have been partially
obscured due to the presence of comigrating BSA (denoted by the asterisk), which was
added as a stabilizing agent during the purification process.
Aliquots of purified 6xHis-Dub proteins were tested for the ability to
deubiquitinate IkBa (Figure 4.2 – panel B). M12 extracts were used as the positive
control for this reaction (lane 1), whereas substrate incubated with reaction buffer alone
(mock reaction) was used as a negative control (lane 2). As another negative control,
lysates from HEK-293T cells transfected with empty vector were subjected to
purification using nickel-NTA beads, and the resulting product (vector) was tested for the
ability to deubiquitinate IkBa (lane 9). This reaction was included to control for any
deubiquitinating activity present in HEK-293T cells that binds to nickel beads in a non-
specific fashion. Comparison of the vector-control reaction (lane 9) with the buffer alone
reaction (lane 2) indicated some IkBa deubiquitinating activity as a background
contaminant of the purification process. When purified wild-type 6xHis-Dub proteins
were used as the activity source, no activity was detected over background (compare
lanes 3 and 6 to lane 9). The catalytically inactive proteins (C60S; see CHAPTER I)
resulted in a comparable signal (compare lanes 5 and 8 to lanes 3, 6, and 9). This
background signal appears to be the result of a contaminating deubiquitinating activity
and not an artifact of nonspecific proteolysis, since preincubation of purified 6xHis-Dub-
1 or 6xHis-Dub-2 with ubiquitin aldehyde (Ub. Al.), a specific inhibitor of
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deubiquitinating enzymes (Hershko and Rose, 1987; Shaeffer and Cohen, 1996),
inhibited the activity (compare lane 3 to 4 and lane 6 to 7). Thus, either 6xHis-Dub
proteins do not possess IkBa-directed deubiquitinating activity, or they do possess a low
level of activity that is masked by one or more endogenous deubiquitinating enzymes that
bind to nickel beads in a non-specific fashion.
Prokaryotic cells do not contain ubiquitin and do not possess deubiquitinating
activity (Voges et al., 1999). Therefore, to circumvent the problem of contaminating
endogenous deubiquitinating activity, recombinant Dub-1 and Dub-2 proteins were
expressed in E coli as fusion proteins with glutathione S-transferase (GST), purified
using glutathione-sepharose (see MATERIALS AND METHODS), and tested for the
ability to deubiquitinate IkBa (Figure 4.3). As above, M12 extracts were used as the
positive control for this reaction (lane 1), and substrate incubated with reaction buffer
alone (mock reaction) was used as a negative control (lane 8). Additional negative
controls included the catalytically inactive mutants GST-Dub-1 (C60S) or GST-Dub-2
(C60S) (lanes 4 and 7), or wild type GST-Dub-1 or GST-Dub-2 that were preincubated
with ubiquitin aldehyde (Ub. Al., lanes 3 and 6). These control reactions resulted in a
comparable signal as compared to the reaction using buffer alone (mock), thus indicating
that no background deubiquitinating activity from E. coli binds nonspecifically to
glutathione beads (compare lanes 3, 4, 6, and 7 to lane 8). When purified GST-Dub-1 and
GST-Dub-2 proteins were tested for their ability to deubiquitinate IkBa, no activity was
detected over the background signal of the assay itself (compare lanes 2 and 5 to lanes 3,
4, 6, 7, and 8). Thus, bacterially expressed GST-Dub-1 and GST-Dub-2 do not appear to
exhibit any IkBa-directed deubiquitinating activity.
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Figure 4.3. Inability of bacterially expressed GST-Dub-1 and GST-Dub-2 to deubiquitinate
IkBa. A. GST-Dub-1 (wild type, lanes 3 - 5; C60S, lanes 6 - 8) and GST-Dub-2 (wild type, lanes 9
- 11; C60S, lanes 12 - 14) protein expression was induced in E. coli using IPTG and purified using
glutathione beads. Aliquots of the bacterial lysates (lanes 3, 4, 6, 7, 9, 10, 12, and 13;
approximately 75 mg) and of purified proteins (lanes 5, 8, 11, and 14; corresponding to
approximately 1 mg input of crude lysates) were analyzed by immunoblotting with a Dub-1
carboxyl terminus antibody (top panel). Lysates (13 mg) of M12 cells expressing (lane 1) or not
expressing (lane 2) S-Tag Dub-2 were used as controls for the western analyses. The purity of the
enriched samples was analyzed by staining the membranes with Ponceau S Red prior to
immunoblot analysis (bottom panel). The dark bands observed in the purified preparations at the
position of the asterisk are BSA which was included as a stabilizer in the purification process. B.
Enriched proteins (corresponding to 2.3 mg input of crude bacterial lysate) were tested for their
ability to deubiquitinate IkBa. M12 cell extracts (final concentration, 2 mg/ml) provided the
source of activity for the positive control reaction (lane 1). Reactions were performed using the
indicated wild type (lanes 2, 3, 5, and 6) and mutant (lanes 4 and 7) Dub proteins that had been
preincubated without (lanes 2, 4, 5, and 7) or with (lanes 3 and 6) ubiquitin aldehyde (Ub. Al.).
Substrate incubated with reaction buffer alone is indicated as “mock” reaction (lane 8).
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IL-3 does not regulate IkBa deubiquitination in FL5.12 cells
The inability to detect deubiquitinating activity associated with bacterially
expressed GST-Dub-1 or GST-Dub-2 might be due to one of several reasons associated
with the bacterial expression of mammalian enzymes. For instance, optimal activity may
require a posttranslational modification event such as phosphorylation, glycosylation, or
proteolytic processing. Alternatively, one or more unidentified cofactors may be required
for activity and/or substrate recognition. These cofactors may be present in lysates of
mammalian cells, which do exhibit deubiquitinating activity (see CHAPTER III).
Therefore, experiments were performed to determine whether deubiquitinating activity
correlates with levels of endogenous Dub-1 protein in cell lysates of FL5.12 cells
following interleukin-3 (IL-3) starvation. Deprivation of IL-3 resulted in reduced levels
of endogenous Dub-1 protein (see CHAPTER II) and reduced stability of IkBa (Sohur et
al., 2000). If the reduced stability of IkBa is associated with a decrease in
IkBa deubiquitination, and if Dub-1 is the primary mediator of IkBa deubiquitination in
FL5.12 cells, then it might be expected that reduced levels of Dub-1 would be associated
with reduced IkBa deubiquitinating activity in these cells.
FL5.12 cells were deprived of IL-3 for 0, 6, or 12 hours and cell lysates were
analyzed for Dub-1 protein expression and for their ability to deubiquitinate IkBa.
Immunoanalysis using a Dub-1 carboxyl terminal antibody demonstrated that Dub-1
protein levels decrease following IL-3 starvation (Figure 4.4 – top panel), consistent with
previous findings (CHAPTER II). Equal amounts of cell lysates (2.5 mg/ml) were then
analyzed for their ability to deubiquitinate IkBa (bottom panel). The results demonstrated
that IkBa-directed deubiquitinating activity does not decrease in parallel with Dub-1
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Figure 4.4. Dub-1 protein levels do not correlate with IkBa deubiquitinating
activity following cytokine starvation of FL5.12 cells. FL5.12 cells were starved of
interleukin-3 (IL-3) and lysed at the indicated time points. Endogenous Dub-1 proteins
were detected by immunoanalysis using a Dub-1 carboxyl terminal antibody (top
panel). Equal amounts of cell lysate protein (2.5 mg/ml) were analyzed for the ability to
deubiquitinate IkBa (bottom panel).
IL-3 starvation (hrs)
Deubiquitinated
T7-IkBa
Dub-1
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protein levels. Although it is possible that Dub-1 may deubiquitinate IkBa, and its
activity is masked in FL5.12 cells by the presence of one or more other activities that are
not regulated by IL-3, these results indicate that Dub-1 is most likely not the major
mediator of IkBa deubiquitination in these cells.
Dub-1 and Dub-2 do not inhibit LPS-induced IkBa degradation
In addition to IkBa, several other components of the NF-kB signal transduction
pathway are modified by ubiquitin conjugation (see CHAPTER I). For example,
cytokine-mediated activation of IKK requires polyubiquitination of TRAF6 (Chen et al.,
1996; Deng et al., 2000; Wang et al., 2001). Therefore, I sought to determine whether
Dub-1 or Dub-2 might regulate the half-life of IkBa indirectly, by deubiquitination of a
protein other than IkBa itself. Dub proteins were overexpressed in M12 B lymphocytes
using a tetracycline-regulated system (see MATERIALS AND METHODS). Since Dub-
1 and Dub-2 expression in the adult mouse have only been detected in hematopoetic cells
such as Ba/F3 pro-B lymphocytes (Zhu et al., 1996) or CTLL-2 T lymphocytes (Zhu et
al., 1997), the murine B lymphocyte cell line M12 was chosen for overexpression of
these proteins. Endogenous Dub-1 and Dub-2 proteins were not detected in these cells by
immunoanalysis using a Dub-1 carboxyl terminus antibody (Figure 4.3 – panel A, lane
2). Thus, the effect of overexpression of ectopic Dub-1 or Dub-2 would not be expected
to be masked by the activity of endogenous Dub-1 or Dub-2.
To determine whether Dub-1 and Dub-2 overexpression had any effect on the
half-life of IkBa, M12 cells were mock-induced or induced to overexpress wild-type S-
Tag-Dub-1, mutant inactive S-Tag-Dub-1 (C60S), or wild-type S-Tag-Dub-2. The cells
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Figure 4.5. Dub-1 and Dub-2 do not stabilize IkBa. A. M12 clones (numbers
indicated) were induced to express S-Tag Dub-1 (WT and C60S) and S-Tag Dub-2
(WT) by removal of tetracycline from cell culture media for 24 hours. Dub-1 and Dub-2
proteins were detected by immunoanalysis of the cell lysates (20 mg) using a Dub-1
carboxyl terminus antibody. B. Twenty-four hours post-induction, protein synthesis was
inhibited by the addition of 20 mg/ml cycloheximide to the cell culture media. Ten
minutes later, cells were stimulated with 20 mg/ml lipopolysaccharide (+ LPS) or left
unstimulated (- LPS), and then harvested at the indicated times post LPS stimulation.
Equal amounts of cell lysate protein (20 mg) were analyzed by western blotting using an
IkBa carboxyl terminus antibody. Results are shown for clones 415 (empty vector), 223
(Dub-1 WT), 326 (Dub-1 C60S), and 120 (Dub-2 WT).
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were then stimulated with bacterial lipopolysaccharide (LPS) to induce IkBa degradation.
The half-life of IkBa was determined following inhibition of protein synthesis with
cycloheximide and immunoanalysis using an antibody to the carboxyl terminus of IkBa.
Expression of exogenous Dub proteins was confirmed in several independently derived
M12 clones by immunoanalysis using a Dub-1 carboxyl terminus antibody (Figure 4.5 –
panel A). Immunoanalysis using an antibody to the carboxyl terminus of
IkBa demonstrated a LPS-induced reduction in the half-life of IkBa in mock-induced
M12 cells (Figure 4.5 – B, compare the top two panels). Analysis of the half-life of
IkBa in clones overexpressing wild-type Dub-1, mutant inactive Dub-1 (C60S), or wild-
type Dub-2 demonstrated that overexpression of these proteins had little or no effect on
the half-life of IkBa following LPS-stimulation (Figure 4.5 – B, compare the bottom four
panels). These data indicated that Dub-1 and Dub-2 do not regulate the half-life of
IkBa in LPS-treated M12 B lymphocytes via deubiquitination of IkBa or an upstream
modulator of IkBa.
Dub-1 and Dub-2 do not inhibit NF-kB DNA-binding activity
To further investigate whether Dub-1 or Dub-2 might regulate NF-kB signal
transduction, I examined the effect of Dub overexpression on NF-kB DNA-binding
activity. M12 cells overexpressing wild-type S-Tag-Dub-1, mutant inactive S-Tag-Dub-1
(C60S), or wild-type S-Tag-Dub-2 were stimulated with LPS or with phorbol esther
(PMA) and the calcium ionophore ionomycin to activate NF-kB. Expression of ectopic
Dub proteins in nuclear (N) and cytoplasmic (C) extracts was detected by
immunoanalysis using a Dub-1 carboxyl terminus antibody (Figure 4.6 – panel A). NF-
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Figure 4.6. Dub-1 and Dub-2 do not inhibit NF-kB DNA binding activity. A. The
expression of S-Tag Dub-1 (WT, clone 223; C60S, clone 314) and S-Tag Dub-2 (WT,
clone 29) were induced in M12 clones by tetracycline withdrawal. Twenty four hours
post-induction, cells were stimulated for one hour with lipopolysaccharide (LPS),
PMA/ionomycin, or left unstimulated. Nuclear (N) and cytoplasmic (C) extracts were
prepared and subjected to immunoanalysis (8 mg) using a Dub-1 carboxyl terminus
antibody. B. NF-kB DNA binding activity was detected in nuclear extracts by
electrophoretic mobility shift assay (EMSA) using a 32P-labelled oligonucleotide
containing an NF-kB consensus binding site. Competition of binding activity in nuclear
extracts of LPS-treated parental M12 cells was performed using 50 x molar excess of
unlabelled wild type or mutant oligonucleotides.
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kB DNA-binding activity was determined in nuclear extracts by electrophoretic mobility
shift assay (EMSA) using a probe corresponding to an NF-kB binding site present in the k
light chain enhancer (Sen and Baltimore, 1986) (panel B). As expected, stimulation of
parental M12 cells or mock-induced M12 cells with LPS or PMA/ionomycin resulted in
an increase in NF-kB DNA-binding activity. However, overexpression of wild-type Dub-
1, mutant inactive Dub-1 (C60S), or wild-type Dub-2 had little or no effect on NF-kB
DNA-binding activity in either stimulated or in unstimulated cells. Therefore, Dub-1 and
Dub-2 do not appear to modulate signal transduction at any point in the NF-kB pathway.
Discussion
Dub-1 and Dub-2 are members of the ubiquitin-processing protease (UBP) family
of deubiquitinating enzymes. I have examined whether Dub-1 and Dub-2 proteins
regulate NF-kB signal transduction, which is regulated at multiple distinct points by
ubiquitin. Several experiments were designed to determine whether polyubiquitinated
IkBa may be a substrate for Dub-1 or Dub-2 in vitro. These experiments revealed that
neither Dub-1 nor Dub-2 exhibited any IkBa-directed deubiquitinating activity over
background levels (Figures 4.2 and 4.3). Furthermore, although FL5.12 cell extracts
express Dub-1 and can deubiquitinate IkBa in vitro, this activity does not correlate with
the levels of Dub-1 protein following IL-3 withdrawal (Figure 4.4). These results indicate
that IkBa is not a substrate for the Dub-1 family of UBPs. Additional experiments
designed to detect a role for Dub-1 and Dub-2 in the regulation of IkBa half-life or NF-
kB activity also indicate that Dub-1 and Dub-2 do not stabilize IkBa following LPS
stimulation of M12 cells (Figure 4.5) and do not modulate NF-kB DNA-binding activity
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in stimulated or unstimulated M12 cells (Figure 4.6). Together, these results provide
strong evidence that Dub-1 and Dub-2 do not serve as positive or negative regulators of
the NF-kB signal transduction pathway.
Several alternative explanations of the findings described in this chapter may be
proposed. For example, bacterially expressed Dub-1 and Dub-2 proteins may lack
deubiquitinating activity in vitro (Figure 4.3) because they lack a specific cofactor or
posttranslational modification necessary for activity. Although no posttranslational
modifications have been described for Dub-1 or Dub-2 to date, it is possible that some
unidentified modification may be necessary for activity and/or substrate recognition. For
example, a number of posttranslational modifications (e.g., glycosylation,
phosphorylation, proteolytic cleavage, methylation, acetylation, or ubiquitin conjugation)
necessary for Dub-1 and Dub-2 activity may not occur in E. coli. In addition, although
the bacterially expressed GST fusion proteins were soluble, they may not be folded
properly due to the lack of an (unidentified) chaperonin activity necessary for their proper
folding. Likewise, recombinant Dub proteins expressed in mammalian cells may be
inactive (Figure 4.2) if their activity is dependent upon an as-yet unidentified signal. For
example, Dub-1 or Dub-2 activity may depend on cytokine stimulation resulting in Dub
phosphorylation or some other posttranslational modification. These considerations
would also apply to the investigations of the effect of Dub proteins on IkBa half-life
(Figure 4.5) and NF-kB activity (Figure 4.6); i.e., Dub activation may require a cofactor
that is not present in M12 cells or may require a signal that is not supplied by LPS or
PMA/ionomycin. Finally, the lack of a correlation between Dub-1 protein levels and
deubiquitinating activity in FL5.12 cell lysates following IL-3 deprivation (Figure 4.4)
113
may be explained by postulating the existence of multiple activities capable of
deubiquitinating IkBa, of which Dub-1 is but one. In this scenario, genuine Dub-1
activity towards IkBa may be masked by the presence of one or more other activities that
are not modulated by IL-3. Despite these alternative explanations, the data presented in
this chapter, taken together, provide strong evidence that Dub-1 and Dub-2 do not play
central roles in the regulation of the NF-kB signaling pathway.
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CHAPTER V
SUMMARY AND FUTURE DIRECTIONS
The last few years have witnessed tremendous advances in our understanding of
the mechanisms by which proteins are recognized and degraded by the ubiquitin-
proteasome pathway (UPP) (Weissman, 2001). In addition, many non-proteolytic roles
have been discovered for ubiquitin and ubiquitin-like proteins (Weissman, 2001). The
plethora of biological events regulated by ubiquitin suggest that protein ubiquitination is
tightly regulated. Like the reversible phosphorylation of proteins, which is modulated by
the opposing actions of protein kinases and protein phosphatases, the ubiquitination state
of proteins is thought to be modulated by the opposing actions of ubiquitinating enzymes
and deubiquitinating enzymes (Wilkinson, 2000). There are several reasons to expect that
deubiquitinating enzymes may work at a pre-proteasomal level to regulate the specificity
of protein targeting to the UPP. These reasons include the relatively high number of
deubiquitinating enzymes as compared to components of the ubiquitination machinery
and the highly specific and regulated expression patterns of some UBP and UCH family
members (Hochstrasser, 1996). Recently, several polyubiquitinated protein substrates
have been identified as candidate substrates for specific UBPs. These substrates include
Liquid Facets (Lqf), which may be deubiquitinated and stabilized by Fat Facets (Faf) in
the Drosophila compound eye (Cadavid et al., 2000; Fischer et al., 1997), and the Ras
guanine nucleotide exchange factor CDC25Mm/Ras-GRF1, which may be deubiquitinated
and stabilized by the mouse deubiquitinating enzyme UBPy (Gnesutta et al., 2001).
115
However, direct biochemical analyses are lacking to verify these enzyme-substrate
relationships. Thus, it remains to be determined whether protein deubiquitination, like
protein dephosphorylation, may modulate signal transduction pathways via the
deubiquitination of a key regulatory proteins in the signaling cascade.
To begin to address these issues, I focused my research efforts on two closely
related deubiquitinating enzymes, Dub-1 and Dub-2. Based on expression data, I
hypothesized that the NF-kB pathway may be regulated by Dub-1 and Dub-2. In
particular, I hypothesized that polyubiquitinated IkBa may be a substrate for Dub-1 and
Dub-2. The rationale for the development of this hypothesis was the observation that
increased levels of Dub-1 or Dub-2 are associated with increased stability of IkBa and
decreased NF-kB activity in pro-B cells (see CHAPTER II and Sohur et al., 2000). My
early experiments (performed while I was a graduate student in Dr. Lawrence Kerr’s
laboratory) examined the effect of Dub-1 of Dub-2 overexpression on NF-kB
transcriptional activity in Jurkat T lymphocytes, as assayed by cotransfection of an NF-
kB-dependent luciferase reporter plasmid and a mammalian expression vector encoding
Dub-1 or Dub-2. Empty expression vector was used as the negative control for these
experiments. These experiments indicated that Dub-1 and Dub-2 did in fact inhibit NF-
kB activity in both stimulated and in unstimulated cells (data not shown). These findings
generated much enthusiasm on my part for pursuing this project. However, when inactive
Dub-1 and Dub-2 constructs (C60S) were later obtained and tested in this assay, the
mutants were also found to inhibit NF-kB activity (data not shown). Two explanations
were proposed to explain these findings: 1) Dub-1 and Dub-2 inhibit NF-kB activity via a
process that does not depend on Dub catalytic activity; or 2) the repression of NF-kB
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activity by overexpression of Dub proteins was an “artifact” of the experimental system.
Several mechanisms could be proposed to explain an artifactual result in this
experimental system. For example, large-scale overexpression of exogenous protein
might squelch the cellular translational machinery and thereby inhibit translation of
luciferase protein used as the reporter. To distinguish between the two explanations
mentioned above, the effect of overexpression of an unrelated protein (b-galactosidase)
on NF-kB activity was assayed in the same system. In these experiments, b-galactosidase
was also observed to inhibit NF-kB activity (data not shown). Since b-galactosidase is not
expected to have any biologically relevant effect on NF-kB activity, the results of this set
of experiments were interpreted as artifactual and therefore inconclusive regarding the
initial hypothesis.
Concurrent with the above experiments, several novel strategies were developed
and utilized for the study of Dub and IkBa. The utilization of these strategies provided
new insights regarding the expression and regulation of these proteins. In CHAPTER II, I
present the development and characterization of a specific antibody that recognizes Dub-
1 and Dub-2. This antibody was used to demonstrate that Dub-1 expression is regulated
by IL-3 in FL5.12 pro-B cells. This observation identifies the FL5.12 cell line as a second
cell line, in addition to the Ba/F3 cell line, that will be useful for the study of Dub-1.
Whole-mount in situ hybridizations of murine embryos revealed that dub-1 mRNA is
expressed in the developing limb buds. Since Dub-1 and other family members have so
far been described only in established hematopoietic cell lines (Zhu et al., 1996; Zhu et
al., 1997), this finding is novel and possibly indicative of a role for Dub-1, or a related
family member, in the control of embryogenesis.
117
In CHAPTER II I present the results of experiments examining the degradation of
Dub-1 and Dub-2. These data indicated that Dub-1, but not Dub-2, is itself a target for
proteolysis by the UPP. In the future, mutagenesis studies (of Dub-1) and experiments
involving domain swapping (between Dub-1 and Dub-2) may be useful for the
identification of sequences involved in targeting Dub-1 to the UPP. It will be particularly
interesting to examine whether the hypervariable domain (the site of greatest diversity
between Dub-1 and Dub-2) or the lysine rich region (potential sites for ubiquitin
conjugation; see Figure 1.5) play a role in Dub-1 ubiquitination. As a first step in the
search for determinants within Dub-1 that are necessary for Dub-1 ubiquitination,
experiments indicated that an intact cysteine 60 is not required for degradation of Dub-1
through the UPP in HEK-293T cells. These results argue against the hypothesis that Dub-
1 acts in “suicide” fashion during protein deubiquitination. However, since the
substrate(s) of Dub proteins have not been identified, this conclusion is difficult to test
directly. The identification of Dub-interacting proteins is one potential strategy that could
be used in the pursuit of Dub substrate(s).
In Chapter III, I present a novel in vitro assay for monitoring the deubiquitination
of IkBa and present the first direct evidence that IkBa is a target for deubiquitinating
enzymes. The deubiquitinating activity detected by this assay is distinct from other types
of activities that have been previously described in that the polyubiquitin ladder appears
to be removed from IkBa in a single cleavage event. In contrast, other deubiquitinating
activities that work at the pre-proteasomal level appear to remove ubiquitin one moiety at
a time from the distal end of the chain. This assay should be useful for a further analysis
of IkBa deubiquitination. For example, future studies could involve the biochemical
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purification of the isopeptidase(s) that catalyzes deubiquitination of IkBa. Were such an
IkBa-directed isopeptidase to be identified, further experiments would be required to
determine the degree of specificity or promiscuity of this enzyme. This determination
could be facilitated by the modification of the assay presented in CHAPTER III to the
analysis of the deubiquitination of other polyubiquitinated proteins. In addition, the
methods outlined in CHAPTER III could be easily extended to test whether Lqf and
CDC25Mm are in fact substrates of Faf and UBPy, respectively (see above).
In Chapter IV, I discuss experiments performed to test the hypothesis that Dub-1
and Dub-2 regulate the NF-kB signal transduction pathway. These experiments revealed
that Dub-1 and Dub-2 do not deubiquitinate IkBa, and that Dub-1 and Dub-2 do not
regulate IkBa stability or NF-kB activation. Very recently, a role for Dub-2 in regulation
of the JAK-STAT pathway in pro-B lymphocytes has been described (Migone et al.,
2001). Our observations that Dub-1 and Dub-2 do not regulate signal transduction
through NF-kB are consistent with the emerging concept of highly specialized roles for
some deubiquitinating enzymes in the control of cellular signaling.
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